nct_id,phase,start_date,enrollment_type,name,official_title,brief_title,American Indian/ Alaska Native,Asian/ Asian Heritage,Black/ Black Heritage,Hawaiian/ Other Pacific Islander,Hispanic/ Latino,Middle Eastern,Mixed,Other,Unknown or Not Reported,White/ White Heritage
NCT00946153,Phase 1/Phase 2,24/07/2009,Actual,lenvatinib,Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC),Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC),0,132,0,0,,,0,,0,0
NCT01295827,Phase 1,04/03/2011,Actual,pembrolizumab,"Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)","Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",4,162,52,4,126,,8,2390,6,2288
NCT01298570,Phase 2,07/04/2011,Actual,regorafenib (bay 73-4506),"Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,0,0,62,0,,,0,,6,294
NCT01354431,Phase 2,31/05/2011,Actual,nivolumab,"A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy",BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC),,,,,0,,,320,16,
NCT01472081,Phase 1,09/02/2012,Actual,nivolumab,"A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma","Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)",2,6,10,0,12,,0,268,32,282
NCT01522443,Phase 3,31/03/2012,Actual,cabozantinib,"A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer,,,,,4,,,228,6,
NCT01585194,Phase 2,29/11/2012,Actual,nivolumab,Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma,Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma,0,1,1,0,2,,0,33,0,33
NCT01592370,Phase 1/Phase 2,02/08/2012,Actual,daratumumab,Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies,An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma,0,6,52,2,40,,0,554,60,550
NCT01599793,Phase 2,31/05/2012,Actual,cabozantinib,A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184,Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer,0,0,1,0,,,0,,0,16
NCT01605227,Phase 3,31/07/2012,Actual,cabozantinib,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100",Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100,2,4,40,0,,,0,,440,1570
NCT01621490,Phase 1,27/09/2012,Actual,nivolumab,An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic),PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma,0,2,0,0,12,,0,252,72,334
NCT01630590,Phase 2,08/01/2014,Actual,cabozantinib,An Observational Study of XL-184 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer,Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer,0,0,1,0,5,,0,56,5,57
NCT01642004,Phase 3,16/10/2012,Actual,nivolumab,An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC),Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017),0,12,16,0,24,,0,242,290,504
NCT01668784,Phase 3,09/10/2012,Actual,nivolumab,"A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy",Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025),2,148,10,2,,,0,,40,1440
NCT01683994,Phase 1/Phase 2,07/09/2012,Actual,cabozantinib,A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,0,2,36,0,4,,0,80,8,50
NCT01693562,Phase 1/Phase 2,05/09/2012,Actual,medi4736,"A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors",A Phase 1/2 Study to Evaluate MEDI4736,0,270,80,10,104,,4,1842,288,1498
NCT01703065,Phase 2,18/06/2013,Actual,cabozantinib,A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer,Cabozantinib in Men With Castration-Resistant Prostate Cancer,0,0,2,0,0,,0,16,6,12
NCT01714739,Phase 1/Phase 2,07/10/2012,Actual,nivolumab,A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors,A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors,2,20,20,,12,,,496,224,574
NCT01721746,Phase 3,21/12/2012,Actual,bms-936558,A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy,A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037),,,,,10,,,354,446,
NCT01721759,Phase 2,16/11/2012,Actual,nivolumab,A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens,Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens,0,2,11,0,0,,,74,48,99
NCT01738438,Phase 2,28/02/2013,Actual,cabozantinib,A Phase II Study of XL184 (Cabozantinib) for Metastatic Triple-Negative Breast Cancer,Cabozantinib for Metastatic Triple Negative BrCa,0,0,3,0,,,0,,0,32
NCT01755195,Phase 2,15/01/2013,Actual,cabozantinib,"A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma",Cabozantinib for Adults With Advanced Soft Tissue Sarcoma,1,10,9,0,11,,0,43,3,33
NCT01761266,Phase 3,01/03/2013,Actual,lenvatinib,"A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma","A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma",2,1320,26,2,34,,,1880,0,552
NCT01772004,Phase 1,31/01/2013,Actual,avelumab,"A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications",Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor),10,326,182,8,,,0,,366,2620
NCT01834651,Phase 2,30/04/2013,Actual,cabozantinib,A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases,A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases,0,0,0,0,,,0,,1,16
NCT01848834,Phase 1,07/05/2013,Actual,pembrolizumab,A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors,Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012),4,96,38,0,24,,4,510,66,446
NCT01876511,Phase 2,30/09/2013,Actual,mk-3475,Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors,"Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)",0,12,14,0,8,,0,216,4,198
NCT01877083,Phase 2,05/04/2013,Actual,lenvatinib,"A Multicenter, Open-Label, Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung",Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung,0,17,0,0,2,,0,23,0,8
NCT01896856,Phase 1/Phase 2,23/10/2013,Actual,regorafenib,A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients,Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer,0,28,32,0,12,,0,224,6,170
NCT01905592,Phase 3,25/02/2014,Actual,niraparib,"A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients","A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",,4,18,,24,,,320,102,356
NCT01913639,Phase 2,31/07/2013,Actual,regorafenib,Phase II Study of FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,0,3,2,0,1,,0,36,5,31
NCT01927419,Phase 2,23/08/2013,Actual,nivolumab,"Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma","Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma",0,2,0,0,2,,0,250,36,278
NCT01928394,Phase 1/Phase 2,24/10/2013,Actual,nivolumab,"A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors,2,36,92,0,36,,0,1472,802,2084
NCT01953692,Phase 1,22/11/2013,Actual,pembrolizumab,A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies,A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013),2,14,20,0,16,,4,328,52,352
NCT01975831,Phase 1,19/12/2013,Actual,durvalumab,"A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors",A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab,0,16,10,2,10,,0,186,26,166
NCT01982955,Phase 1/Phase 2,23/12/2013,Actual,tepotinib,"A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second-Line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-TKI Therapy (INSIGHT)",Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT),0,176,0,0,,,0,,0,0
NCT01988493,Phase 1/Phase 2,06/01/2014,Actual,tepotinib,"A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects With MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function","Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma",0,232,0,0,0,,0,232,0,0
NCT01993719,Phase 2,12/12/2013,Actual,pembrolizumab,A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 With the Administration of Pembrolizumab in the Retreatment Arm,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma,0,0,0,0,0,,0,66,0,66
NCT02005471,Phase 3,17/03/2014,Actual,venetoclax,"A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab",A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL),0,20,4,0,14,,0,744,56,718
NCT02008227,Phase 3,11/03/2014,Actual,atezolizumab,"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy",A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,,,,,180,,,2162,108,
NCT02011945,Phase 1,07/02/2014,Actual,nivolumab,"A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination Dasatinib (BMS-354825) Plus Nivolumab (BMS-936558) in Patients Chronic Myeloid Leukemia (CML)",A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia,0,2,8,0,2,,0,24,36,52
NCT02017717,Phase 3,07/02/2014,Actual,nivolumab,A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma,A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients,2,14,16,,20,,,674,386,1004
NCT02036502,Phase 1,14/02/2014,Actual,pembrolizumab,A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination With Backbone Treatments for Subjects With Multiple Myeloma,A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023),0,2,16,0,26,,0,102,26,136
NCT02038933,Phase 2,05/03/2014,Actual,nivolumab,"A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT",Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139),0,24,10,0,6,,0,128,112,204
NCT02038946,Phase 2,26/03/2014,Actual,nivolumab,"A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Follicular Lymphoma (FL)",Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140),0,3,1,0,5,,0,49,39,87
NCT02041533,Phase 3,27/03/2014,Actual,nivolumab,"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",,,,,14,,,560,508,
NCT02048722,Phase 2,13/06/2014,Actual,regorafenib,"Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma","Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",0,0,3,0,0,,0,31,1,27
NCT02053376,Phase 2,31/01/2014,Actual,regorafenib,A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,0,0,3,0,,,0,,0,40
NCT02054520,Phase 2,30/06/2014,Actual,nivolumab,A Phase 2b Study of Immune Checkpoint Inhibition With or Without Dorgenmeltucel-L (HyperAcute Melanoma) Immunotherapy for Stage IV Melanoma Patients,Immunotherapy Study for Patients With Stage IV Melanoma,0,0,0,0,0,,0,94,0,94
NCT02055820,Phase 1/Phase 2,17/11/2013,Actual,venetoclax,"A Phase Ib/II, Open-Label Study Evaluating the Safety, Efficacy and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL","A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL",0,12,8,6,8,,0,374,274,374
NCT02061761,Phase 1/Phase 2,13/03/2014,Actual,bms-936558,"A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (Relatlimab, BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies","A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies",0,10,18,2,8,,0,204,16,166
NCT02066636,Phase 3,09/04/2014,Actual,nivolumab,A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen,A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen,10,84,210,4,82,,0,2762,28,2532
NCT02079636,Phase 1,28/03/2014,Actual,pembrolizumab,A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC,A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),4,14,10,0,14,,0,266,4,256
NCT02080260,Phase 2,06/06/2014,Actual,regorafenib,A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas,A Study of Regorafenib in Advanced Pancreatic Cancer Patients,0,0,8,0,0,,0,20,0,12
NCT02085070,Phase 2,31/03/2014,Actual,mk-3475,A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,0,2,2,2,8,,0,118,12,116
NCT02087423,Phase 2,25/02/2014,Actual,medi4736,"A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen",A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer,,282,10,,54,,,834,,596
NCT02089685,Phase 1/Phase 2,17/03/2014,Actual,pembrolizumab,A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029),Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),0,10,4,0,8,,4,520,92,542
NCT02101736,Phase 2,30/06/2014,Actual,cabozantinib,A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults,Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults,0,6,8,2,6,,0,82,10,66
NCT02115373,Phase 1/Phase 2,18/05/2014,Actual,tepotinib,"A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects With MET+ Advanced Hepatocellular Carcinoma With Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment",c-Met Second-Line Hepatocellular Carcinoma,0,4,2,0,,,2,,54,70
NCT02115542,Phase 2,05/06/2014,Actual,regorafenib,Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers,Single Agent Regorafenib in Refractory Advanced Biliary Cancers,0,1,1,0,4,,0,35,2,35
NCT02118337,Phase 1/Phase 2,19/05/2014,Actual,durvalumab,"A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies","A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies",2,4,6,2,12,,0,178,24,160
NCT02119676,Phase 2,31/03/2014,Actual,regorafenib,"A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",Study of Ruxolitinib in Colorectal Cancer Patients,0,42,54,2,,,70,,16,608
NCT02130466,Phase 1/Phase 2,29/05/2014,Actual,pembrolizumab,A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),0,10,0,0,6,,0,338,24,358
NCT02132598,Phase 2,31/12/2015,Actual,cabozantinib,A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification,Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases,0,0,0,0,,,0,,0,5
NCT02132754,Phase 1,27/06/2014,Actual,pembrolizumab,Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination With Pembrolizumab in Subjects With Advanced Malignancies,Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001),0,0,0,0,0,,0,0,464,0
NCT02142738,Phase 3,25/08/2014,Actual,pembrolizumab,A Randomized Open-Label Phase III Trial of Pembrolizumab Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer,Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),2,92,8,2,12,,0,566,36,502
NCT02155647,Phase 2,03/07/2014,Actual,avelumab,"A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma",Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200),0,12,4,0,66,,0,266,156,312
NCT02164240,Phase 1,31/07/2014,Actual,regorafenib,"A Non-randomized, Open-label Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors",Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,0,0,1,0,0,,0,13,0,12
NCT02180061,Phase 1,15/07/2014,Actual,pembrolizumab,Phase Ib Study of MK-3475 in Subjects With Advanced Melanoma,Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041),0,84,0,0,0,,0,84,0,0
NCT02181738,Phase 2,12/08/2014,Actual,nivolumab,"Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects",Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),,,,,10,,,378,200,
NCT02195011,Phase 2,31/07/2014,Actual,regorafenib,A Two Arm Safety Study of Regorafenib Before or After SIR-Spheres Microspheres (90Y) for the Treatment of Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,Safety Study of Regorafenib and SIR-Spheres�� Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,0,0,6,0,,,0,,0,46
NCT02207530,Phase 2,23/10/2014,Actual,medi4736,"A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,0,4,5,0,1,,0,109,5,100
NCT02213289,Phase 2,20/01/2015,Actual,nivolumab,PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma,PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,0,4,14,0,,,6,,0,136
NCT02220894,Phase 3,30/10/2014,Actual,pembrolizumab,"A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Na��ve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)",Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),30,752,46,2,,,98,,0,1620
NCT02227667,Phase 2,02/12/2014,Actual,medi4736,Phase II Study to Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer,Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer,0,2,0,0,1,,0,15,2,12
NCT02231749,Phase 3,16/10/2014,Actual,nivolumab,"A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma",Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),0,186,26,0,58,,,1074,1102,1938
NCT02242942,Phase 3,31/12/2014,Actual,venetoclax,"A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions",Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,2,,8,6,86,,,698,182,798
NCT02243371,Phase 2,02/01/2015,Actual,nivolumab,"A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS-207 With or Without Nivolumab in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma",GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,0,20,8,0,4,,4,168,14,154
NCT02243579,Phase 2,15/10/2014,Actual,pembrolizumab,A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome,Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome,0,0,3,0,,,0,,1,20
NCT02252042,Phase 3,17/11/2014,Actual,pembrolizumab,A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer,Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),4,62,20,0,,,14,,62,828
NCT02253992,Phase 1/Phase 2,29/09/2014,Actual,nivolumab,A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma,An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma,0,2,18,0,4,,0,228,96,292
NCT02255097,Phase 2,24/10/2014,Actual,pembrolizumab,A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab,Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055),1,7,11,0,9,,0,153,10,153
NCT02257528,Phase 2,18/05/2015,Actual,nivolumab,"A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer","Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",0,0,5,0,2,,0,22,3,18
NCT02259725,Phase 2,16/08/2016,Actual,regorafenib,Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors,Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors,0,0,0,0,2,,0,1,0,3
NCT02260531,Phase 2,30/11/2014,Actual,cabozantinib,A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases,Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases,,,4,,,,2,2,,64
NCT02263508,Phase 3,08/12/2014,Actual,pembrolizumab,"A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)",Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma,0,22,6,0,44,,,1410,4,1366
NCT02267603,Phase 2,25/11/2014,Actual,pembrolizumab,A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC),Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer,0,1,0,0,,,0,,4,45
NCT02281084,Phase 2,06/07/2015,Actual,durvalumab,"A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine",Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes,0,4,2,2,8,,,124,6,114
NCT02287233,Phase 1/Phase 2,31/12/2014,Actual,venetoclax,A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Na��ve Subjects With Acute Myelogenous Leukemia Who Are ��� 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy,A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Na��ve Participants With Acute Myelogenous Leukemia,,4,4,,,,,,6,174
NCT02289222,Phase 1/Phase 2,30/12/2014,Actual,mk-3475,1454GCC: Phase I/II Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma,1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma,0,2,18,0,0,,0,46,4,26
NCT02291055,Phase 1/Phase 2,30/04/2015,Actual,medi4736,Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer,A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer,,4,20,,24,,,138,0,114
NCT02301039,Phase 2,31/03/2015,Actual,pembrolizumab,SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,2,8,18,0,16,,2,252,34,244
NCT02303990,Phase 1,08/01/2015,Actual,pembrolizumab,RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,0,0,3,0,59,,0,0,0,56
NCT02304458,Phase 1/Phase 2,02/02/2015,Actual,nivolumab,"A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,2,14,24,0,42,,4,234,28,212
NCT02306850,Phase 2,31/01/2015,Actual,pembrolizumab,"Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating the Efficacy of Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma",Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,0,0,0,0,,,0,,0,10
NCT02311361,Phase 1/Phase 2,25/03/2015,Actual,durvalumab,A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,0,2,16,0,2,,0,128,2,110
NCT02316002,Phase 2,21/01/2015,Actual,pembrolizumab,Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer,Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer,0,1,2,0,,,0,,8,40
NCT02318277,Phase 1/Phase 2,05/01/2015,Actual,medi4736,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)",A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203),,8,22,,14,,,334,12,314
NCT02319044,Phase 2,15/04/2015,Actual,medi4736,"A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",0,18,20,0,,,0,,36,460
NCT02320058,Phase 2,05/03/2015,Actual,nivolumab,A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy,"An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself",,,,,10,,,228,0,
NCT02322814,Phase 2,12/03/2015,Actual,atezolizumab,"A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer","A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread",0,60,10,0,32,,0,294,22,258
NCT02323126,Phase 2,09/02/2015,Actual,nivolumab,"A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer",Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,,14,,,,,,2,4,108
NCT02327078,Phase 1/Phase 2,26/11/2014,Actual,nivolumab,"A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)","A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)",0,6,14,2,34,,0,566,42,564
NCT02331368,Phase 2,30/06/2015,Actual,mk-3475,Phase 2 Multi-center Study of Anti-Programmed-Death-1 [Anti-PD-1] During Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma,Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,,,,,2,,,26,1,
NCT02332980,Phase 2,19/02/2015,Actual,pembrolizumab,A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL),Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas,0,0,4,0,0,,0,114,18,124
NCT02335411,Phase 2,03/02/2015,Actual,pembrolizumab,A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059),A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059),0,146,10,0,42,,4,558,52,448
NCT02335424,Phase 2,24/02/2015,Actual,pembrolizumab,A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer,Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052),2,26,8,0,22,,2,326,30,332
NCT02336165,Phase 2,26/02/2015,Actual,durvalumab,Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients With Glioblastoma (GBM),Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma,0,4,4,0,,,0,,26,284
NCT02337491,Phase 2,09/02/2015,Actual,pembrolizumab,Phase II Study of Pembrolizumab (MK-3475) With and Without Bevacizumab for Recurrent Glioblastoma,Pembrolizumab +/- Bevacizumab for Recurrent GBM,,,,,4,,,130,26,
NCT02337686,Phase 2,28/04/2015,Actual,pembrolizumab,Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma,Pembrolizumab in Treating Patients With Recurrent Glioblastoma,0,0,0,0,,,0,,1,14
NCT02339558,Phase 2,21/07/2015,Actual,nivolumab,Multicenter Phase II Study of Nivolumab in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma,Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer,0,37,1,1,,,0,,2,4
NCT02340975,Phase 1/Phase 2,31/03/2015,Actual,medi4736,"A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma","A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",0,98,0,0,4,,0,222,2,126
NCT02341625,Phase 1/Phase 2,19/06/2015,Actual,nivolumab,"A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,0,8,6,0,2,,0,228,28,232
NCT02343952,Phase 2,31/03/2015,Actual,pembrolizumab,A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179,Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC,,4,3,,,,,,3,174
NCT02348008,Phase 1/Phase 2,31/03/2015,Actual,mk-3475,Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003,Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:,0,0,0,0,10,,0,96,28,110
NCT02348216,Phase 1/Phase 2,21/04/2015,Actual,axicabtagene ciloleucel,A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma,Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma,,20,22,,54,,,554,4,454
NCT02349633,Phase 1/Phase 2,14/05/2015,Actual,avelumab,PHASE 1/2 OPEN-LABEL STUDY OF PF-06747775 (EPIDERMAL GROWTH FACTOR RECEPTOR T790M INHIBITOR) IN PATIENTS WITH ADVANCED EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (DEL 19 OR L858R �� T790M) NON-SMALL CELL LUNG CANCER,Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),,94,,,,,,2,2,32
NCT02351739,Phase 2,30/04/2015,Actual,pembrolizumab,Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study),Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer,2,2,6,0,2,,0,148,2,138
NCT02354586,Phase 2,23/03/2015,Actual,niraparib,"A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens",A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens,1,16,20,,,,,,32,394
NCT02358031,Phase 3,19/03/2015,Actual,pembrolizumab,A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma,A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),28,344,42,0,270,,50,1354,148,1292
NCT02359019,Phase 2,28/02/2015,Actual,pembrolizumab,Phase II Study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients,MK-3475 as Maintenance Therapy in Extensive Stage SCLC,,,6,,,1,,,1,37
NCT02359851,Phase 2,31/05/2015,Actual,pembrolizumab,A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients With Advanced Uveal Melanoma,Pembrolizumab in Treating Patients With Advanced Uveal Melanoma,0,0,0,0,,,0,,0,5
NCT02362997,Phase 2,30/04/2015,Actual,pembrolizumab,"A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma","Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL",0,2,6,0,2,,4,110,100,104
NCT02364076,Phase 2,31/03/2015,Actual,pembrolizumab,Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas,Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma,0,4,2,1,,,0,,0,33
NCT02368886,Phase 2,27/03/2015,Actual,regorafenib,Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC),Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,2,10,18,0,,,0,,4,198
NCT02369874,Phase 3,09/09/2015,Actual,medi4736,"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,,226,8,,88,,,1380,60,1182
NCT02370498,Phase 3,11/05/2015,Actual,pembrolizumab,"A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine",A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061),14,368,12,0,102,,8,1082,0,782
NCT02375672,Phase 2,28/05/2015,Actual,pembrolizumab,"A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186",Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,0,0,4,0,0,,0,29,1,26
NCT02383433,Phase 2,14/06/2016,Actual,regorafenib,A Phase II Study of Second-Line Therapy With Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,0,0,0,0,0,,0,2,0,2
NCT02387996,Phase 2,09/03/2015,Actual,nivolumab,A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects With Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment With a Platinum Agent,A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer,0,30,2,0,2,,,159,116,231
NCT02388906,Phase 3,16/03/2015,Actual,nivolumab,"A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)",Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma,0,86,0,2,28,,0,846,944,1718
NCT02393248,Phase 1/Phase 2,27/02/2015,Actual,pembrolizumab,"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)","Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)",,,,,30,,,364,8,
NCT02395172,Phase 3,24/03/2015,Actual,avelumab,"A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer That Has Progressed After a Platinum-Containing Doublet",Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200),,,,,202,,,1208,174,
NCT02395627,Phase 2,04/05/2015,Actual,pembrolizumab,"Reversing Therapy Resistance With Epigenetic-immune Modification: Phase II Trial of Vorinostat, Tamoxifen and Pembrolizumab in Hormone Receptor Expressing Advanced Breast Cancer",Reversing Therapy Resistance With Epigenetic-Immune Modification,0,6,8,0,4,,0,58,30,46
NCT02401048,Phase 1/Phase 2,31/05/2015,Actual,medi4736,"A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas,0,0,4,0,,,0,,8,110
NCT02402036,Phase 2,28/02/2015,Actual,regorafenib,Regorafenib in Metastatic Colorectal Cancer: An Exploratory Biomarker Study,A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer,0,0,5,0,0,,0,7,6,2
NCT02403271,Phase 1/Phase 2,31/03/2015,Actual,durvalumab,"A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,1,5,11,0,6,,0,116,1,104
NCT02409355,Phase 3,07/05/2015,Actual,atezolizumab,"A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Gemcitabine+Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer",A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111),0,4,0,0,0,,0,16,0,12
NCT02409368,Phase 2,29/04/2015,Actual,nivolumab,"An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC","An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC",0,4,6,0,122,,0,1502,18,1596
NCT02413489,Phase 2,02/09/2015,Actual,daratumumab,"An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma","An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma",,12,,,6,,,62,20,44
NCT02419417,Phase 1/Phase 2,19/06/2015,Actual,nivolumab,"A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies",Study of BMS-986158 in Subjects With Select Advanced Cancers,0,8,4,0,6,,0,74,102,138
NCT02421354,Phase 2,14/05/2015,Actual,nivolumab,"Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis","Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis",0,0,0,0,,,0,,0,8
NCT02423343,Phase 1/Phase 2,01/01/2015,Actual,nivolumab,"A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma",0,0,4,0,,,0,,0,78
NCT02426892,Phase 2,23/12/2015,Actual,nivolumab,Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors,Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,0,0,6,0,2,,0,29,4,25
NCT02428192,Phase 2,22/04/2015,Actual,nivolumab,A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus,Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma,0,0,2,0,2,,0,38,2,36
NCT02431559,Phase 1/Phase 2,02/12/2015,Actual,durvalumab,"Phase 1/2 Study of Chemoimmunotherapy With Toll-like Receptor 8 Agonist Motolimod (VTX-2337) + Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin is Indicated","Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer",0,4,4,0,10,,0,92,12,90
NCT02432274,Phase 1/Phase 2,29/12/2014,Actual,lenvatinib,Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,0,0,0,0,32,,12,94,122,128
NCT02434354,Phase 1,30/04/2015,Actual,pembrolizumab,A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,0,0,0,0,0,,0,30,0,30
NCT02440425,Phase 2,20/10/2015,Actual,pembrolizumab,Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer,Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,1,0,4,0,3,,0,39,2,35
NCT02447003,Phase 2,11/06/2015,Actual,pembrolizumab,A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086),Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086),2,78,52,0,32,,6,440,42,364
NCT02448303,Phase 2,31/05/2015,Actual,pembrolizumab,A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma,Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer,0,12,16,0,4,,0,132,4,104
NCT02450331,Phase 3,05/10/2015,Actual,atezolizumab,"A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection",A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection,,,,,50,,,1452,116,
NCT02451930,Phase 1,04/09/2015,Actual,pembrolizumab,"An Open-Label, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of the Combination of Necitumumab With Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer",A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,0,14,2,0,2,,0,44,122,100
NCT02452424,Phase 1/Phase 2,02/07/2015,Actual,pembrolizumab,Phase 1/2a Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors,A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,0,4,10,0,,,0,,6,136
NCT02452463,Phase 2,29/06/2015,Actual,durvalumab,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy",Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy,0,0,0,0,,,0,,0,16
NCT02454179,Phase 2,31/05/2015,Actual,pembrolizumab,A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma,0,8,12,0,12,,0,140,0,132
NCT02454478,Phase 1,01/07/2015,Actual,lenvatinib,Phase 1 Study of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic RCC,Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC),0,7,0,0,0,,0,7,0,0
NCT02454933,Phase 3,15/07/2015,Actual,medi4736,"A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination With MEDI4736 Versus AZD9291 Monotherapy in Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy (CAURAL)",Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,0,52,0,0,2,,0,56,0,6
NCT02459119,Phase 2,31/05/2015,Actual,regorafenib,"A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy",Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),0,0,1,0,,,0,,0,16
NCT02460198,Phase 2,25/08/2015,Actual,pembrolizumab,A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164),Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164),0,66,14,0,8,,0,238,2,168
NCT02464657,Phase 1/Phase 2,31/07/2015,Actual,nivolumab,"Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)","Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)",0,8,2,0,,,0,,4,74
NCT02466009,Phase 2,31/03/2015,Actual,regorafenib,Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study,Regorafenib in Metastatic Colorectal Cancer,0,0,6,1,1,,0,26,0,20
NCT02472977,Phase 1/Phase 2,13/07/2015,Actual,nivolumab,A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors,Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors,0,0,6,0,4,,0,70,8,76
NCT02481830,Phase 3,14/09/2015,Actual,nivolumab,"An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)",Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer,2,282,6,0,20,,0,534,588,844
NCT02488759,Phase 1/Phase 2,13/10/2015,Actual,daratumumab,"Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors","An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors",12,112,34,0,,,0,,48,950
NCT02489448,Phase 1/Phase 2,30/11/2015,Actual,medi4736,Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer,Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,,,22,,12,,8,,8,82
NCT02493361,Phase 2,17/08/2015,Actual,pembrolizumab,"An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation",Trial of pIL-12/MK-3475 in Metastatic Melanoma,0,0,0,0,1,,0,22,4,21
NCT02494583,Phase 3,31/07/2015,Actual,pembrolizumab,"A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),58,414,26,4,290,,44,1198,48,970
NCT02498600,Phase 2,29/06/2015,Actual,nivolumab,"Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",0,8,14,2,8,,0,188,8,172
NCT02499835,Phase 1/Phase 2,01/07/2015,Actual,pembrolizumab,"Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer","Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer",0,0,2,0,0,,0,130,2,130
NCT02499952,Phase 2,31/01/2016,Actual,pembrolizumab,A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206,Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors,0,0,1,0,0,,0,12,0,11
NCT02500121,Phase 2,11/11/2015,Actual,pembrolizumab,"A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182",Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer,0,4,14,0,,,0,,4,192
NCT02500797,Phase 2,30/07/2015,Actual,nivolumab,Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery,2,4,24,4,,,0,,10,284
NCT02500901,Phase 1,31/03/2016,Actual,niraparib,Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer With Enzalutamide and the Poly (ADP- Ribose) Polymerase (PARP) Inhibitor Niraparib: Hoosier Cancer Research Network GU14-202,Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),0,0,0,0,0,,0,2,0,2
NCT02501473,Phase 1/Phase 2,03/02/2016,Actual,pembrolizumab,Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin's Lymphoma,Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142),0,2,4,0,10,,0,88,14,86
NCT02509507,Phase 1/Phase 2,05/02/2016,Actual,pembrolizumab,"A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318)",Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611,0,38,2,0,16,,,240,0,212
NCT02511184,Phase 1,31/10/2015,Actual,pembrolizumab,A PHASE 1B STUDY OF CRIZOTINIB IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH UNTREATED ADVANCED ALK-TRANSLOCATED NON SMALL CELL LUNG CANCER,Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients,,2,,,,,,2,,14
NCT02519348,Phase 2,19/10/2015,Actual,durvalumab,"A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma","A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma",6,514,50,6,42,,2,824,8,280
NCT02521870,Phase 1/Phase 2,30/09/2015,Actual,pembrolizumab,"A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)",A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,,,,,20,,,424,16,
NCT02526017,Phase 1,08/09/2015,Actual,nivolumab,A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers,Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers,0,26,36,0,54,,,578,20,534
NCT02528357,Phase 1,11/09/2015,Actual,pembrolizumab,"A Phase I, Open-Label Study of GSK3174998 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Subjects With Selected Advanced Solid Tumors",GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),,7,5,,,3,,,5,119
NCT02529072,Phase 1,31/01/2016,Actual,nivolumab,AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors,Nivolumab With DC Vaccines for Recurrent Brain Tumors,0,0,0,0,0,,0,12,0,12
NCT02538510,Phase 1/Phase 2,08/10/2015,Actual,pembrolizumab,A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies,Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,4,12,0,2,2,,0,96,2,82
NCT02538666,Phase 3,13/10/2015,Actual,nivolumab,"A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)","An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy",,,,,80,,,990,744,
NCT02541565,Phase 1,24/11/2015,Actual,pembrolizumab,MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,,4,,,,,,,,26
NCT02541604,Phase 1/Phase 2,30/11/2015,Actual,atezolizumab,"An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) In Pediatric and Young Adult Patients With Previously Treated Solid Tumors","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors",0,6,12,0,32,,4,102,92,100
NCT02546986,Phase 2,09/10/2015,Actual,pembrolizumab,"A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer",Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,0,2,10,0,,,0,,14,174
NCT02549209,Phase 2,22/08/2017,Actual,pembrolizumab,Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma,Pembro/Carbo/Taxol in Endometrial Cancer,0,1,3,0,,,0,,3,39
NCT02553499,Phase 1,12/11/2015,Actual,pembrolizumab,A Phase 1 Trial of MK-1248 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors.,Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001),0,0,0,0,0,,0,74,0,74
NCT02555657,Phase 3,13/10/2015,Actual,pembrolizumab,A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119),Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),16,376,34,0,,,48,,44,726
NCT02559687,Phase 2,02/12/2015,Actual,pembrolizumab,A Phase II Study of Pembrolizumab Monotherapy in Third Line Previously Treated Subjects With Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE-180),Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180),0,42,2,0,2,,0,108,17,71
NCT02563002,Phase 3,30/11/2015,Actual,pembrolizumab,A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177),Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),0,100,28,0,42,,0,518,82,458
NCT02563548,Phase 1,22/10/2015,Actual,pembrolizumab,A Phase 1B Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors,A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors,0,4,6,0,8,,0,100,8,94
NCT02563925,Not Applicable,18/09/2015,Actual,durvalumab,A Pilot Study of Brain Irradiation and Tremelimumab in Metastatic Breast Cancer,Brain Irradiation and Tremelimumab in Metastatic Breast Cancer,0,5,5,0,0,,0,28,1,17
NCT02564263,Phase 3,01/12/2015,Actual,pembrolizumab,"A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),2,496,12,2,88,,12,1122,76,702
NCT02569242,Phase 3,14/12/2015,Actual,nivolumab,"ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Esophageal Cancer Refractory or Intolerant to Combination Therapy With Fluoropyrimidine and Platinum-based Drugs",Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,0,802,0,0,,,0,,0,36
NCT02572167,Phase 1/Phase 2,31/10/2015,Actual,nivolumab,A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy,A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma,2,10,4,0,28,,8,148,10,154
NCT02574078,Phase 1/Phase 2,23/11/2015,Actual,nivolumab,A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370),A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC),4,44,44,0,34,,,654,8,576
NCT02574455,Phase 3,07/11/2017,Actual,sacituzumab govitecan,"An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments",Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC),,44,124,,90,,,974,48,836
NCT02575807,Phase 1/Phase 2,08/03/2016,Actual,pembrolizumab,"A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer","Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer",0,2,0,0,4,,0,60,4,58
NCT02576509,Phase 3,07/12/2015,Actual,nivolumab,"A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)",An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma,2,664,10,0,30,,0,700,776,790
NCT02576574,Phase 3,29/10/2015,Actual,avelumab,"A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC",Avelumab in First-line NSCLC (JAVELIN Lung 100),0,484,14,2,144,,0,2200,254,1758
NCT02576977,Phase 3,19/10/2015,Actual,pembrolizumab,A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183),Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183),0,58,48,6,26,,6,454,32,374
NCT02576990,Phase 2,02/12/2015,Actual,pembrolizumab,A Phase II Study of Pembrolizumab (MK-3475) in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS),Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170),0,0,2,0,10,,0,116,42,150
NCT02579616,Phase 2,23/10/2015,Actual,lenvatinib,"An Open-Label, Multicenter Phase 2 Study of E7080/ LENVIMA (Lenvatinib Mesylate) in Subjects With Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy",Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy,0,26,0,0,0,,0,26,0,0
NCT02579863,Phase 3,19/10/2015,Actual,pembrolizumab,A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Na��ve Multiple Myeloma (KEYNOTE 185).,Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),0,108,24,2,16,,2,558,58,472
NCT02580058,Phase 3,21/12/2015,Actual,avelumab,"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER",A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),2,266,20,2,12,,,1076,54,832
NCT02581631,Phase 1/Phase 2,11/02/2016,Actual,nivolumab,A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436),An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas,0,8,26,0,8,,0,116,168,250
NCT02581982,Phase 2,06/04/2016,Actual,pembrolizumab,Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma,Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,0,0,3,0,0,,0,26,4,21
NCT02584829,Phase 1/Phase 2,06/11/2015,Actual,avelumab,Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination With MHC Class I Up-Regulation and the Anti-PD-L1 Antibody Avelumab,Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma,0,0,0,0,0,,0,16,0,16
NCT02587650,Phase 2,26/03/2015,Actual,regorafenib,A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma,"Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",0,0,0,0,0,,0,1,0,1
NCT02589496,Phase 2,26/03/2016,Actual,pembrolizumab,Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis,Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis,0,61,0,0,0,,0,61,0,0
NCT02591615,Phase 2,31/03/2016,Actual,mk-3475,Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer,Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,0,0,16,4,0,,0,182,4,158
NCT02592551,Phase 2,11/05/2016,Actual,medi4736,Window Of Opportunity Phase II Study Of MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,0,2,0,0,6,,0,42,4,42
NCT02593786,Phase 1/Phase 2,07/01/2016,Actual,nivolumab,"A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)","A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors",0,116,0,0,,,0,,0,0
NCT02596035,Phase 4,08/01/2016,Actual,nivolumab,A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374),An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma,0,0,26,0,32,,0,250,10,250
NCT02596971,Phase 1/Phase 2,22/12/2015,Actual,atezolizumab,A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Lymphoma,"A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)",0,8,0,0,10,,0,160,20,166
NCT02598960,Phase 1/Phase 2,14/10/2015,Actual,nivolumab,"A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors","An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.",0,48,6,0,8,,0,202,380,524
NCT02599324,Phase 1/Phase 2,01/12/2015,Actual,pembrolizumab,A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors,Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,2,138,8,0,36,,0,486,4,374
NCT02599402,Phase 3,20/12/2015,Actual,nivolumab,Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401,Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,0,2,0,0,5,,0,515,23,521
NCT02599649,Phase 2,21/03/2016,Actual,nivolumab,Phase II Combination of Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),0,0,0,0,,,0,,0,20
NCT02601313,Phase 2,09/11/2015,Actual,axicabtagene ciloleucel,A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma,Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2),,,2,2,26,,,162,6,170
NCT02603419,Phase 1,10/03/2016,Actual,avelumab,A PHASE 1 PHARMACOKINETIC-PHARMACODYNAMIC STUDY OF AVELUMAB (MSB0010718C) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED STAGE CLASSICAL HODGKIN'S LYMPHOMA,Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS),0,4,6,2,6,,0,62,4,52
NCT02603432,Phase 3,25/04/2016,Actual,avelumab,"A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY",A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100),0,312,4,0,60,,0,1168,316,940
NCT02603887,Early Phase 1,20/07/2016,Actual,pembrolizumab,"Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma",Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma,0,1,0,0,0,,0,13,0,12
NCT02608684,Phase 2,08/02/2016,Actual,pembrolizumab,A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,0,1,0,0,1,,0,17,0,17
NCT02609503,Phase 2,16/05/2016,Actual,pembrolizumab,Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy,Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin,1,0,0,0,1,,0,28,3,25
NCT02609984,Phase 2,29/04/2015,Actual,atezolizumab,"A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1",Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002),4,8,8,4,26,,,146,14,146
NCT02611960,Phase 3,18/04/2016,Actual,pembrolizumab,"A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)",Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122),0,444,2,0,8,,0,458,0,20
NCT02612779,Phase 2,09/02/2016,Actual,nivolumab,"A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.",A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.,2,2,14,,12,,,142,2,122
NCT02617589,Phase 3,01/03/2016,Actual,nivolumab,A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498),"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",,,,,10,,,414,696,
NCT02622074,Phase 1,27/01/2016,Actual,pembrolizumab,A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173),Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),0,42,0,0,6,,0,114,0,78
NCT02625610,Phase 3,24/12/2015,Actual,avelumab,"A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction",Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100),4,240,8,0,68,,,878,134,664
NCT02625623,Phase 3,28/12/2015,Actual,avelumab,"A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),0,188,4,0,60,,,616,144,472
NCT02626000,Phase 1,06/04/2016,Actual,pembrolizumab,"A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137),0,1,1,0,2,,,35,0,33
NCT02630186,Phase 1/Phase 2,24/02/2016,Actual,mpdl3280a,A Phase 1b/2 Study of the Safety and Efficacy of Rociletinib (CO-1686) Administered in Combination With MPDL3280A in Patients With Activating EGFR Mutation-positive (EGFRm) Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,0,1,0,0,,,0,,0,2
NCT02631746,Phase 2,21/02/2017,Actual,nivolumab,Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma,Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma,0,0,1,0,1,,0,1,3,0
NCT02632409,Phase 3,22/03/2016,Actual,nivolumab,"A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)","An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer",2,310,10,0,74,,0,570,798,1072
NCT02636725,Phase 2,19/04/2016,Actual,pembrolizumab,A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS),Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas,0,2,0,1,8,,1,25,0,29
NCT02639065,Phase 2,27/04/2016,Actual,durvalumab,A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012,A Study of Durvalumab (MEDI4736) in Esophageal Cancer,,,,,1,,,,1,72
NCT02639910,Phase 2,30/11/2016,Actual,venetoclax,"A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor",Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi,0,0,0,0,,,0,,0,48
NCT02641093,Phase 2,31/01/2016,Actual,pembrolizumab,Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,0,0,2,0,,,0,,3,87
NCT02643303,Phase 1/Phase 2,28/12/2016,Actual,durvalumab,"A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist Poly-ICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers,0,2,14,0,2,,0,108,8,90
NCT02648282,Phase 2,18/07/2016,Actual,pembrolizumab,A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas,"Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer",0,1,7,0,,,0,,1,49
NCT02650999,Phase 1/Phase 2,31/01/2016,Actual,pembrolizumab,Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas,Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas,0,0,0,0,,,0,,0,12
NCT02655016,Phase 3,07/07/2016,Actual,niraparib,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy",A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy,2,50,24,2,,,,,78,1310
NCT02656706,Phase 2,31/07/2016,Actual,nivolumab,Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma,0,0,0,0,,,0,,0,21
NCT02657434,Phase 3,30/04/2016,Actual,atezolizumab,"A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132),4,272,12,0,76,,0,968,188,792
NCT02657889,Phase 1/Phase 2,15/04/2016,Actual,niraparib,Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer,Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer,0,10,18,0,14,,0,226,14,206
NCT02658019,Phase 2,06/05/2016,Actual,pembrolizumab,Phase II Study of Pembrolizumab (Keytruda��) in Advanced Hepatocellular Carcinoma (HCC),Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma,0,1,1,0,9,,0,20,0,27
NCT02659059,Phase 2,15/02/2016,Actual,nivolumab,A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC),Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer,0,6,46,0,24,,0,588,50,582
NCT02659540,Phase 1,13/10/2016,Actual,nivolumab,A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade (Ipilimumab and Nivolumab) Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma,0,4,0,0,,,0,,0,36
NCT02664181,Phase 2,06/06/2017,Actual,nivolumab,"Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer",Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial,2,0,2,0,0,,0,26,4,18
NCT02667587,Phase 3,09/05/2016,Actual,nivolumab,A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma,"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",,136,16,,36,,,738,700,1238
NCT02669914,Phase 2,12/09/2016,Actual,medi4736,A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors,MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors,0,0,2,0,0,,0,8,0,6
NCT02671435,Phase 1/Phase 2,22/02/2016,Actual,durvalumab,A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors,A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors,2,116,34,6,72,,2,688,36,576
NCT02673333,Phase 2,29/02/2016,Actual,pembrolizumab,A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma,Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma,0,0,2,0,1,,0,38,1,36
NCT02674061,Phase 2,25/02/2016,Actual,pembrolizumab,"A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100),0,60,10,2,18,,2,686,50,676
NCT02677324,Phase 2,09/05/2016,Actual,abt199,Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenstr��m Macroglobulinemia,Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenstr��m Macroglobulinemia,0,0,0,0,,,0,,3,30
NCT02684253,Phase 2,11/02/2016,Actual,nivolumab,"A Phase II Randomized Controlled Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)","Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",0,22,8,0,8,,0,122,16,84
NCT02684461,Phase 2,13/09/2016,Actual,pembrolizumab,Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel After Standard First-Line Induction Chemotherapy in Advanced NSCLC,Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel,0,0,6,0,2,,0,38,0,34
NCT02684617,Phase 1,29/03/2016,Actual,pembrolizumab,Phase Ib Trial of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Subjects With Hematologic Malignancies (KEYNOTE-155).,Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155),0,8,12,0,10,,0,134,0,124
NCT02685826,Phase 1/Phase 2,25/04/2016,Actual,durvalumab,"A Phase 1/2 Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) in Combination With Lenalidomide (LEN) With and Without Dexamethasone (DEX)in Subjects With Newly Diagnosed Multiple Myeloma (NDMM)",A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma,0,4,2,0,,,0,,12,94
NCT02686164,Phase 1,18/04/2016,Actual,lenvatinib,"An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors",Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors,0,1,5,0,6,,0,24,5,19
NCT02688608,Phase 2,31/10/2016,Actual,pembrolizumab,Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer,Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,0,0,0,0,0,,0,6,2,4
NCT02689284,Phase 1/Phase 2,31/01/2016,Actual,pembrolizumab,"A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer","Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer",2,102,6,0,4,,2,182,8,74
NCT02690948,Phase 1/Phase 2,01/02/2016,Actual,pembrolizumab,A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma,Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,0,0,0,0,8,,0,24,4,28
NCT02701400,Phase 2,14/04/2016,Actual,durvalumab,A Randomized Study of Tremelimumab Plus Durvalumab Combination With or Without Radiation in Relapsed Small Cell Lung Cancer,Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer,0,2,6,0,0,,0,36,2,26
NCT02702388,Phase 2,08/06/2017,Actual,lenvatinib,"A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile","A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",0,44,10,2,14,,0,276,90,172
NCT02702401,Phase 3,26/05/2016,Actual,pembrolizumab,A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240),Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240),12,330,38,2,70,,16,692,66,426
NCT02702414,Phase 2,31/05/2016,Actual,pembrolizumab,A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Advanced Hepatocellular Carcinoma (KEYNOTE-224),Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224),0,32,8,2,8,,2,286,18,264
NCT02703714,Phase 2,06/05/2016,Actual,pembrolizumab,Phase II Trial of Pembrolizumab (MK-3475) With GM-CSF Induction in Advanced Biliary Cancers,Pembrolizumab and GM-CSF in Biliary Cancer,0,9,1,0,3,,0,39,2,30
NCT02706405,Phase 1,15/11/2016,Actual,durvalumab,"A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma",JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,2,4,2,0,0,,0,56,2,50
NCT02708641,Phase 2,04/10/2016,Actual,pembrolizumab,A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ��� 60 With Acute Myeloid Leukemia (AML) Who Are Not Transplantation Candidates,A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ��� 60 With AML,0,0,1,0,,,0,,0,11
NCT02713373,Phase 1/Phase 2,05/08/2016,Actual,pembrolizumab,A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer,Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery,0,0,2,0,,,0,,0,42
NCT02713867,Phase 3,24/05/2016,Actual,nivolumab,"A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks","A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks",0,8,30,0,14,,0,466,260,674
NCT02716805,Phase 1,13/12/2016,Actual,durvalumab,"A Phase 1 Study to Assess Safety and Tolerability of Tremelimumab and Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant (HDT/ASCT)","Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant",0,1,2,0,0,,0,6,0,3
NCT02718417,Phase 3,19/05/2016,Actual,avelumab,"A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER JAVELIN OVARIAN 100",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),2,526,14,,,,,34,,1420
NCT02720484,Phase 2,30/03/2016,Actual,nivolumab,Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma,Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer,0,0,0,0,0,,0,10,0,10
NCT02723006,Phase 1,22/06/2016,Actual,nivolumab,"An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",0,0,2,0,0,,0,38,8,40
NCT02724878,Phase 2,31/07/2016,Actual,atezolizumab,Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,0,0,3,0,4,,2,56,2,53
NCT02726581,Phase 3,10/08/2016,Actual,nivolumab,"An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma","An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma",0,0,26,0,12,,0,192,140,310
NCT02728830,Early Phase 1,30/06/2016,Actual,pembrolizumab,A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin,A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers,0,0,1,0,0,,0,14,2,13
NCT02730130,Phase 2,03/06/2016,Actual,pembrolizumab,A Multicenter Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients,Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients,1,1,1,0,1,,0,14,4,12
NCT02730546,Phase 1/Phase 2,24/06/2016,Actual,pembrolizumab,"Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",0,0,0,0,0,,0,31,0,31
NCT02733042,Phase 1/Phase 2,11/05/2016,Actual,durvalumab,"A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",0,26,2,0,4,,,156,110,126
NCT02737072,Phase 1,30/09/2016,Actual,durvalumab,"A Phase 1a/1b Study of CXCR4 Peptide Antagonist (LY2510924) Administered in Combination With the Anti-PD-L1 Antibody, Durvalumab (MEDI4736), in Advanced Refractory Solid Tumors",A Study of LY2510924 and Durvalumab in Participants With Solid Tumors,0,0,0,0,0,,0,18,0,18
NCT02737475,Phase 1/Phase 2,17/06/2016,Actual,nivolumab,A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors,An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread,2,8,8,0,12,,0,178,146,310
NCT02740920,Phase 2,12/05/2016,Actual,pembrolizumab,A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker,Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker,,,,,0,,,7,2,
NCT02741570,Phase 3,05/10/2016,Actual,nivolumab,"An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,24,226,44,2,166,,0,812,954,1560
NCT02743494,Phase 3,14/07/2016,Actual,nivolumab,"A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer",An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer,4,234,18,,88,,,858,678,1296
NCT02743819,Phase 2,28/06/2016,Actual,pembrolizumab,Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody,Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma,0,0,1,0,1,,0,68,2,68
NCT02748564,Phase 2,21/03/2017,Actual,pembrolizumab,Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma,Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,0,0,0,0,0,,0,20,0,20
NCT02748889,Phase 1/Phase 2,31/03/2016,Actual,mpdl3280a,"An Open Label, Randomized Phase I/II Trial of Carboplatin Plus Etoposide With ot Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer",Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,0,0,2,0,,,0,,0,0
NCT02750514,Phase 2,09/05/2016,Actual,nivolumab,"A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)",An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer,0,32,38,0,18,,0,384,218,490
NCT02754141,Phase 1/Phase 2,21/06/2016,Actual,nivolumab,A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors,An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab,0,16,10,0,4,,0,184,290,436
NCT02756611,Phase 3,22/06/2016,Actual,venetoclax,"Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)",A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL),,2,3,,9,,,248,2,252
NCT02758717,Phase 2,13/05/2016,Actual,nivolumab,"Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy",Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma,0,2,2,0,,,0,,3,39
NCT02759575,Phase 1/Phase 2,30/04/2016,Actual,pembrolizumab,"A Phase I/II Study of Chemo Radiation Plus the Anti-Programmed Death-1 (Anti-PD-1) Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma",A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma,0,0,1,0,0,,0,9,0,8
NCT02764333,Phase 2,06/05/2016,Actual,durvalumab,A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,0,2,0,0,2,,0,27,1,26
NCT02767934,Phase 2,13/01/2017,Actual,pembrolizumab,A Phase II Study of Anti-PD-1 Antibody (MK-3475; Pembrolizumab) for the Treatment of Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia,Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia,0,1,1,0,1,,0,11,0,10
NCT02768558,Phase 3,17/10/2016,Actual,nivolumab,"Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer",Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC,0,0,2,0,0,,0,16,0,14
NCT02768701,Phase 2,18/10/2016,Actual,pembrolizumab,Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,0,0,8,0,,,1,,3,28
NCT02771626,Phase 1/Phase 2,01/08/2016,Actual,nivolumab,"A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer","Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)",0,4,16,0,16,,0,216,18,202
NCT02775435,Phase 3,09/06/2016,Actual,pembrolizumab,"A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),4,216,14,2,,,0,,22,860
NCT02775903,Phase 2,03/06/2016,Actual,durvalumab,"A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)",An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML),0,6,4,0,32,,,300,210,300
NCT02787005,Phase 2,01/07/2016,Actual,pembrolizumab,Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199),Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199),0,66,22,0,28,,2,702,90,642
NCT02788279,Phase 3,05/07/2016,Actual,regorafenib,"A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370),0,82,20,4,50,,0,650,54,592
NCT02792192,Phase 1/Phase 2,13/06/2016,Actual,atezolizumab,"A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With or Without Bacille Calmette-Gu��rin in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer",Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Gu��rin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants,0,0,8,0,2,,2,46,2,36
NCT02794883,Phase 2,01/11/2016,Actual,durvalumab,"A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Malignant Glioma With Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination to Determine Immunologic Changes From Treatment",Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma,0,4,2,0,10,,0,62,0,66
NCT02807454,Phase 2,07/07/2016,Actual,daratumumab,"A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)",A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma,,,,,0,,,74,0,
NCT02808143,Phase 1,10/02/2017,Actual,pembrolizumab,A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer,Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer,0,2,2,0,0,,0,16,4,12
NCT02811861,Phase 3,13/10/2016,Actual,pembrolizumab,"A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,2,450,12,2,110,,,2038,88,1574
NCT02818920,Phase 2,31/01/2017,Actual,pembrolizumab,"Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study",Neoadjuvant Pembrolizumab,0,0,1,0,0,,0,25,2,22
NCT02819518,Phase 3,27/07/2016,Actual,pembrolizumab,"A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),24,380,76,0,330,,38,1348,136,1196
NCT02819804,Phase 1,17/08/2017,Actual,nivolumab,Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL),Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,0,0,0,0,0,,0,1,0,1
NCT02821000,Phase 1,08/07/2016,Actual,pembrolizumab,A Phase Ib Study of Pembrolizumab (MK-3475) in Chinese Subjects With Locally Advanced or Metastatic Melanoma (Keynote-151),Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151),0,103,0,0,,,0,,0,0
NCT02821754,Phase 2,05/07/2016,Actual,durvalumab,A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),2,12,24,0,8,,0,100,4,66
NCT02823574,Phase 2,08/11/2016,Actual,nivolumab,"A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,0,10,16,0,58,,0,340,488,788
NCT02828124,Phase 1/Phase 2,23/08/2016,Actual,nivolumab,A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma,A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer,,18,0,,,,,,,2
NCT02829918,Phase 2,05/10/2016,Actual,nivolumab,A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers,Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers,0,3,8,0,8,,0,46,1,42
NCT02830594,Phase 2,05/10/2016,Actual,pembrolizumab,Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect,"Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",,5,1,,1,,,,,7
NCT02832167,Phase 2,22/02/2016,Actual,nivolumab,An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies,An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread,0,9,20,0,11,,0,158,77,203
NCT02834247,Phase 1,12/08/2016,Actual,nivolumab,A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors,A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,0,6,8,0,2,,0,74,10,64
NCT02835690,Phase 1,04/08/2016,Actual,pembrolizumab,"An Open-label, Randomized Phase I Study Investigating Safety, Tolerability, Pharmacokinetics, and Efficacy of Pembrolizumab (MK-3475) in Chinese Subjects With Non-Small-Cell Lung Cancer","Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)",,,,,0,,,84,0,
NCT02837029,Phase 1,31/07/2016,Actual,nivolumab,Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma,Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer,0,0,2,0,4,,0,30,4,28
NCT02837042,Phase 2,31/10/2016,Actual,pembrolizumab,Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy,Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma,0,0,0,0,0,,0,6,0,6
NCT02846792,Phase 1/Phase 2,14/06/2017,Actual,nivolumab,A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients With Advanced Stage Non-small Cell Lung Cancer That Have Progressed Through First Line Platinum Doublet Chemotherapy,"Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer",0,0,0,0,0,,0,5,0,5
NCT02848651,Phase 2,23/09/2016,Actual,atezolizumab,A Phase II Single-Arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Clinical Evaluation of Novel Blood-Based Diagnostics,A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer,1,1,13,0,3,,0,147,4,135
NCT02853305,Phase 3,15/09/2016,Actual,pembrolizumab,"A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),2,362,16,0,166,,8,1526,568,1392
NCT02853331,Phase 3,16/09/2016,Actual,pembrolizumab,"A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)",Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),0,274,36,0,74,,0,1528,164,1368
NCT02853344,Phase 2,30/09/2016,Actual,pembrolizumab,"A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)",Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427),4,56,2,0,6,,0,520,26,486
NCT02857426,Phase 2,21/10/2016,Actual,nivolumab,"A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)",A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL),0,30,0,0,2,,0,88,46,98
NCT02859324,Phase 1/Phase 2,20/09/2016,Actual,nivolumab,"A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure",A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC),,,2,,0,,,24,36,22
NCT02859454,Phase 2,06/08/2016,Actual,avelumab,A Phase II Study of Avelumab in Subjects With Recurrent Respiratory Papillomatosis,Avelumab for People With Recurrent Respiratory Papillomatosis,0,2,0,0,1,,1,12,0,10
NCT02860546,Phase 2,29/08/2016,Actual,nivolumab,"A Phase 2 Study With Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Patients With Microsatellite Stable Refractory Metastatic Colorectal Cancer",A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC,0,0,4,0,,,0,,2,12
NCT02862535,Phase 1,20/09/2016,Actual,nivolumab,A Phase 1b Study to Evaluate the Safety and Tolerability of Andecaliximab (GS-5745) as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Subjects With Gastric or Gastroesophageal Junction Adenocarcinoma,Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma,0,68,0,0,0,,0,68,0,0
NCT02864251,Phase 3,17/03/2017,Actual,nivolumab,"Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy",A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy,0,686,0,0,0,,0,342,398,42
NCT02864316,Phase 2,31/12/2016,Actual,nivolumab,Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure,Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure,0,0,0,0,0,,0,8,0,8
NCT02864381,Phase 2,01/09/2016,Actual,nivolumab,"A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma",Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma,,4,4,,10,,,248,78,232
NCT02864394,Phase 3,07/09/2016,Actual,pembrolizumab,"A Multinational, Multicenter, Phase III, Randomized Open-label Trial of Pembrolizumab Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer",Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033),0,716,0,0,58,,0,792,0,134
NCT02865811,Phase 2,15/09/2016,Actual,pembrolizumab,"A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer","Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",0,3,0,0,0,,1,23,3,22
NCT02867592,Phase 2,08/05/2017,Actual,cabozantinib,"Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",0,16,28,4,42,,2,166,46,132
NCT02870920,Phase 2,10/08/2016,Actual,durvalumab,A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies,Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer,6,38,10,2,,,0,,2,302
NCT02872116,Phase 3,12/10/2016,Actual,nivolumab,"A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer",Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer,52,1020,48,0,,,0,,162,2780
NCT02873195,Phase 2,07/07/2017,Actual,atezolizumab,"BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer",Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer,0,16,30,2,,,0,,4,204
NCT02875067,Phase 1/Phase 2,29/08/2016,Actual,pembrolizumab,"A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma","Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",0,0,1,0,2,,2,4,0,3
NCT02875613,Phase 2,31/01/2017,Actual,avelumab,"An Open-label, Single-arm, Multi-institutional Phase II Trial of Avelumab for Recurrent, Metastatic Nasopharyngeal Carcinoma",Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer,0,2,1,0,,,0,,0,1
NCT02879318,Phase 2,22/08/2016,Actual,durvalumab,"A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma",0,32,4,0,,,0,,4,320
NCT02879994,Phase 2,15/09/2016,Actual,pembrolizumab,"A Phase II Study of Pembrolizumab in EGFR Mutant, Tyrosine Kinase Inhibitor Na��ve Treatment Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer",0,5,0,0,0,,0,10,1,6
NCT02880228,Phase 2,16/09/2016,Actual,pembrolizumab,"Phase 2 Trial of Pembrolizumab, Lenalidomide, and Dexamethasone for Initial Therapy of Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation","Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant",0,0,0,0,0,,0,10,2,10
NCT02880371,Phase 1/Phase 2,01/09/2016,Actual,pembrolizumab,"A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,0,2,10,0,4,,0,144,20,136
NCT02885324,Phase 2,18/05/2017,Actual,cabozantinib,Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children,Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children,0,0,1,0,,,0,,0,3
NCT02888665,Phase 1/Phase 2,05/12/2016,Actual,pembrolizumab,A Trial of Pembrolizumab in Combination With Doxorubicin as Treatment for Patients With Advanced Sarcomas,Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery,4,4,2,0,10,,0,62,12,54
NCT02892734,Phase 2,18/09/2017,Actual,nivolumab,A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial,Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer,0,0,0,0,0,,0,3,0,3
NCT02898116,Phase 1/Phase 2,10/05/2017,Actual,durvalumab,"A Phase 1/2 Study of ALK Inhibitor, Ensartinib (X-396), and Anti-PD-L1, Durvalumab (MEDI4736), in Subjects With ALK-rearranged (ALK-positive) Non-small Cell Lung Cancer (NSCLC)","Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer",0,0,0,0,0,,0,2,1,1
NCT02899078,Phase 1/Phase 2,15/11/2016,Actual,nivolumab,Phase Ib/II Trial of Ibrutinib Plus Nivolumab in Patients With Previously-Treated Metastatic Renal Cell Cancer,Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer,1,2,1,0,2,,0,29,0,27
NCT02899195,Phase 2,13/06/2017,Actual,durvalumab,"Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma",Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma,0,2,2,0,,,0,,4,47
NCT02899299,Phase 3,29/11/2016,Actual,nivolumab,"A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients,12,130,0,0,76,,0,516,654,1032
NCT02900560,Phase 2,20/12/2016,Actual,pembrolizumab,"Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer,0,6,0,0,,,0,,2,60
NCT02901548,Phase 2,16/02/2017,Actual,durvalumab,"A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Gu��rin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder",Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Gu��rin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder,0,0,0,0,0,,0,17,0,17
NCT02901899,Phase 2,30/11/2016,Actual,pembrolizumab,An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer,"Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",0,2,5,0,1,,0,43,3,36
NCT02904226,Phase 1/Phase 2,31/08/2016,Actual,nivolumab,"Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies",JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors,0,16,34,4,28,,0,392,72,326
NCT02904954,Phase 2,02/12/2016,Actual,durvalumab,"A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC)","Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer",0,10,14,0,12,,0,108,0,96
NCT02905266,Phase 3,27/10/2016,Actual,nivolumab,"Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma",A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma,0,0,2,0,4,,0,108,114,196
NCT02908672,Phase 3,13/01/2017,Actual,atezolizumab,"A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma",A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma,4,22,2,2,94,,0,896,58,978
NCT02910583,Phase 2,28/09/2016,Actual,venetoclax,Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-na��ve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL),2,16,6,2,32,,0,598,48,588
NCT02915783,Phase 2,20/02/2017,Actual,lenvatinib,"A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease",A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,0,0,1,0,1,,0,28,5,27
NCT02919683,Phase 2,30/11/2016,Actual,nivolumab,Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,0,2,2,0,,,0,,0,56
NCT02921269,Phase 2,10/03/2017,Actual,atezolizumab,"A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer","Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer",0,0,1,0,1,,0,9,2,9
NCT02923531,Phase 1/Phase 2,07/12/2016,Actual,nivolumab,A Phase 1B/2A Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma,Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma,0,0,0,0,0,,0,8,1,9
NCT02924883,Phase 2,26/09/2016,Actual,atezolizumab,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy",A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy,0,144,12,2,22,,2,360,34,232
NCT02926833,Phase 1/Phase 2,29/09/2016,Actual,atezolizumab,A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL),Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL),,10,,,6,,,62,2,56
NCT02927925,Phase 2,14/02/2017,Actual,daratumumab,"An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type","A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type",0,32,0,0,0,,0,32,0,0
NCT02933944,Phase 1,30/09/2016,Actual,pembrolizumab,A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer,Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer,0,1,0,0,,,0,,0,5
NCT02934503,Phase 2,23/01/2017,Actual,pembrolizumab,A Phase II Study of Pembrolizumab and Dynamic PD-L1 Expression in Extensive Stage Small Cell Lung Cancer (SCLC),Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC),0,0,0,0,0,,0,5,0,5
NCT02939300,Phase 2,15/02/2018,Actual,nivolumab,Phase II Trial of Ipilimumab and Nivolumab in Leptomeningeal Metastases,Ipilimumab and Nivolumab in Leptomeningeal Metastases,0,2,0,0,,,0,,2,14
NCT02939651,Phase 2,26/10/2016,Actual,pembrolizumab,"A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients With Metastatic High Grade Neuroendocrine Tumors",A Study of Pembrolizumab in Patients With Neuroendocrine Tumors,,,,,3,,,18,0,
NCT02944565,Phase 2,22/02/2017,Actual,daratumumab,Daratumumab Infusion Acceleration,Daratumumab in Treating Patients With Multiple Myeloma,0,0,3,0,,,0,,1,24
NCT02949219,Phase 2,24/03/2017,Actual,pembrolizumab,A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas,Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,0,0,7,0,,,0,,3,30
NCT02951156,Phase 3,16/12/2016,Actual,avelumab,"PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) JAVELIN DLBCL","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",,,,,2,,,56,4,54
NCT02951819,Phase 2,09/11/2016,Actual,daratumumab,"Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma",A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma,0,4,22,0,10,,0,182,20,162
NCT02952586,Phase 3,28/11/2016,Actual,avelumab,A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK,Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100),2,376,38,2,42,,,1318,104,906
NCT02953457,Phase 2,29/06/2017,Actual,durvalumab,"A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation",0,0,0,0,,,0,,4,156
NCT02953561,Phase 1/Phase 2,20/02/2017,Actual,avelumab,An Open-Label Phase Ib/II Study of Avelumab in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia,Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia,0,0,3,0,,,0,,1,15
NCT02954536,Phase 2,03/11/2016,Actual,pembrolizumab,"Phase II Trial of Pembrolizumab in Combination With Trastuzumab, Fluoropyrimidine, and Platinum Chemotherapy in First Line Stage IV HER2-positive Metastatic Esophagogastric (EG) Cancer",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,0,2,3,0,1,,0,36,0,32
NCT02959437,Phase 1/Phase 2,27/02/2017,Actual,pembrolizumab,"A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)",Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),,,,,12,,,120,8,
NCT02960854,Phase 1,07/12/2016,Actual,nivolumab,"Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (Nivolumab) in Participants With Severe Sepsis or Septic Shock.",A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.,0,0,12,0,6,,0,56,4,46
NCT02963090,Phase 2,20/05/2017,Actual,pembrolizumab,A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer,Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer,0,0,2,0,0,,0,18,0,16
NCT02963831,Phase 1/Phase 2,07/09/2017,Actual,durvalumab,"A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies,0,6,8,0,14,,0,108,12,108
NCT02964078,Phase 2,25/04/2017,Actual,pembrolizumab,"Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin���) and Pembrolizumab (Anti-PD1, Keytruda���) for Therapy of Metastatic Kidney Cancer",Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer,0,1,0,0,2,,0,25,1,25
NCT02967133,Phase 2,31/12/2016,Actual,nivolumab,"Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study",A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer,0,0,2,0,0,,0,14,0,12
NCT02968940,Phase 2,17/03/2017,Actual,avelumab,"A Phase II, Open-label, Single Arm, Multicenter Study of Avelumab With Hypofractionated Radiation in Adult Subjects With Transformed IDH Mutant Glioblastoma",Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma,0,0,0,0,2,,0,4,1,5
NCT02981524,Phase 2,26/05/2017,Actual,pembrolizumab,A Phase 2 Study of GVAX Colon Vaccine (With Cyclophosphamide) and Pembrolizumab in Patients With Mismatch Repair-Proficient (MMR-p) Advanced Colorectal Cancer,Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer,0,1,3,0,1,,0,16,0,13
NCT02982720,Phase 2,05/07/2017,Actual,pembrolizumab,A Phase II Multi-center Study Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and Sylatron (Peginterferon Alfa-2b) HCRN:GI16-263,Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron,0,0,0,0,0,,0,2,5,1
NCT02982954,Phase 4,16/01/2017,Actual,nivolumab,"Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)",A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer,2,4,18,0,20,,0,400,12,388
NCT02985957,Phase 2,26/03/2017,Actual,nivolumab,"A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer","A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)",,,,,6,,,540,156,
NCT02989714,Phase 1/Phase 2,16/03/2017,Actual,nivolumab,"Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer","Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",0,0,2,0,0,,0,13,0,11
NCT02993523,Phase 3,02/02/2017,Actual,venetoclax,"A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Na��ve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy",A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Na��ve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy,2,218,12,0,,,0,,0,654
NCT02996110,Phase 2,02/02/2017,Actual,nivolumab,"A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)",A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma,,,,,16,,,224,124,
NCT02996474,Phase 1/Phase 2,16/12/2016,Actual,pembrolizumab,Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia,Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia,0,1,3,0,0,,0,10,0,6
NCT02998528,Phase 3,04/03/2017,Actual,nivolumab,"Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC",A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC),0,446,26,0,14,,0,516,496,522
NCT03000179,Phase 2,03/03/2017,Actual,avelumab,Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine,Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma,0,0,0,0,0,,0,7,1,8
NCT03000452,Phase 2,14/03/2017,Actual,daratumumab,"MEDI4736-MM-005 (FUSION MM-005): A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab.",A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM),0,0,1,,,,,,2,15
NCT03003520,Phase 2,28/02/2017,Actual,durvalumab,"A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,0,0,0,0,0,,,94,0,90
NCT03003676,Phase 1,31/12/2016,Actual,pembrolizumab,"A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After PD1 Blockade","A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",0,2,2,0,,,0,,0,38
NCT03004183,Phase 2,01/07/2017,Actual,pembrolizumab,Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab,SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,0,12,18,0,8,,0,104,0,82
NCT03006848,Phase 2,16/02/2017,Actual,avelumab,"A Phase II Trial of Avelumab, A Fully Human Antibody That Targets Cells Expressing PD-L1, in Patients With Recurrent or Progressive Osteosarcoma",A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma,,,2,,,,,,2,14
NCT03006887,Phase 1,12/01/2017,Actual,pembrolizumab,An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors,Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors,0,6,0,0,0,,0,6,0,0
NCT03006926,Phase 1,13/02/2017,Actual,lenvatinib,An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma,A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma,0,64,4,0,6,,0,168,72,102
NCT03008369,Phase 2,31/05/2017,Actual,lenvatinib,Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma,Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery,,,,,0,,,3,0,
NCT03011034,Phase 2,14/02/2017,Actual,daratumumab,A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,,,,,8,,,56,4,
NCT03016312,Phase 3,10/01/2017,Actual,atezolizumab,"A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen","A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",2,272,30,2,58,,4,1388,174,1154
NCT03018080,Phase 2,12/06/2017,Actual,pembrolizumab,LCI-BRE-H2N-PEPP-001: A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients With Metastatic HER2-Negative Breast Cancer (The PePPy Trial),Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer,0,2,20,0,0,,0,74,6,58
NCT03019588,Phase 3,16/02/2017,Actual,pembrolizumab,"A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine",Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063),0,188,0,0,0,,0,188,0,0
NCT03023423,Phase 1/Phase 2,23/12/2016,Actual,daratumumab,"A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer",A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer,0,0,0,0,2,,0,166,62,166
NCT03025880,Phase 2,28/06/2017,Actual,pembrolizumab,"A Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Pembrolizumab and Gemcitabine in Patients With HER2-negative Advanced Breast Cancer (ABC) ""PANGEA-Breast""",Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC,0,0,0,0,,,0,,0,72
NCT03026166,Phase 1/Phase 2,30/03/2017,Actual,nivolumab,A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,,,4,,4,,,78,4,78
NCT03029598,Phase 1/Phase 2,14/03/2017,Actual,pembrolizumab,"Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",0,1,0,0,0,,0,29,0,28
NCT03029832,Phase 2,27/04/2017,Actual,atezolizumab,"A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy",A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy,0,0,0,0,,,0,,0,10
NCT03038100,Phase 3,08/03/2017,Actual,atezolizumab,"A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",22,610,42,4,154,,0,2374,148,1850
NCT03041181,Phase 2,27/01/2017,Actual,nivolumab,Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor,Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor,0,0,2,0,0,,0,6,0,4
NCT03043599,Phase 1/Phase 2,13/02/2017,Actual,nivolumab,Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer,Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer,0,1,0,0,0,,0,20,2,19
NCT03043664,Phase 1/Phase 2,01/07/2017,Actual,pembrolizumab,Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors,Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors,0,1,7,0,0,,0,19,8,9
NCT03043872,Phase 3,27/03/2017,Actual,durvalumab,"A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)",Durvalumab �� Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN),,1240,24,,92,,,3876,28,2660
NCT03044730,Phase 2,25/05/2017,Actual,pembrolizumab,Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer,Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,0,0,3,0,1,,0,28,3,25
NCT03045328,Phase 2,26/09/2017,Actual,venetoclax,An Open Label Phase 2 Trial of Venetoclax With Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma,Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL,0,0,2,0,0,,1,22,0,19
NCT03048500,Phase 2,12/07/2017,Actual,nivolumab,Parallel Proof of Concept Phase 2 Study of Nivolumab and Metformin Combination Treatment in Advanced Non-small Cell Lung Cancer With and Without Prior Treatment With PD-1/PD-L1 Inhibitors,Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery,0,1,3,0,0,,0,16,2,12
NCT03050060,Phase 2,09/06/2017,Actual,nivolumab,"ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy With Concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma","Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",0,2,2,0,3,,0,16,2,15
NCT03050814,Phase 2,05/04/2017,Actual,avelumab,A Randomized Phase II Trial of Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in Patients With Previously Untreated Metastatic or Unresectable Colorectal Cancer,Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004,0,0,14,0,2,,0,56,4,44
NCT03051672,Phase 2,22/05/2017,Actual,pembrolizumab,A Phase II Study Of Pembrolizumab In Combination With Palliative Radiotherapy For Metastatic Hormone Receptor Positive Breast Cancer,Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC,0,0,0,0,0,,0,8,0,8
NCT03056001,Phase 2,01/05/2017,Actual,pembrolizumab,"A Pilot Study Evaluating the Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab in Patients With Metastatic or Unresectable Soft Tissue Sarcoma","Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma",0,0,4,0,3,,0,26,4,23
NCT03057106,Phase 2,15/02/2017,Actual,durvalumab,A Randomized Trial of Durvalumab and Tremelimumab �� Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC),Durvalumab and Tremelimumab �� Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,4,26,8,2,,,0,,10,552
NCT03057613,Phase 2,10/05/2017,Actual,pembrolizumab,A Phase II Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck,The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck,0,0,0,0,0,,0,18,0,18
NCT03057795,Phase 2,03/04/2017,Actual,nivolumab,A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma,Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma,,,,,17,,,39,3,
NCT03061188,Phase 1,23/05/2017,Actual,nivolumab,Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes,Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes,0,6,0,0,2,,0,28,0,24
NCT03062358,Phase 3,27/04/2017,Actual,pembrolizumab,A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394),Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394),0,906,0,0,0,,0,906,0,0
NCT03063632,Phase 2,13/10/2017,Actual,pembrolizumab,A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2),Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S��zary Syndrome and Advanced Synovial Sarcoma,0,0,8,0,,,0,,0,48
NCT03065400,Phase 2,14/06/2017,Actual,pembrolizumab,PD-1 Inhibition in Advanced Myeloproliferative Neoplasms,PD-1 Inhibition in Advanced Myeloproliferative Neoplasms,0,0,1,0,,,0,,0,9
NCT03066778,Phase 3,02/05/2017,Actual,pembrolizumab,"A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),0,172,2,0,38,,2,792,128,678
NCT03068455,Phase 3,11/04/2017,Actual,nivolumab,"A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma",An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma,2,16,10,,88,,,1494,2130,3636
NCT03069352,Phase 3,23/05/2017,Actual,venetoclax,"A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Na��ve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy",A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,,118,6,,,,,,,298
NCT03070392,Phase 2,16/10/2017,Actual,pembrolizumab,"A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,2,0,0,0,,,0,,96,658
NCT03071094,Phase 1/Phase 2,27/07/2017,Actual,nivolumab,A Phase I/IIa Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC),A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC),0,0,0,0,0,,0,6,36,6
NCT03071406,Phase 2,14/03/2017,Actual,nivolumab,"A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma",Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma,0,0,0,0,0,,0,100,0,100
NCT03072160,Phase 2,16/06/2017,Actual,pembrolizumab,Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,0,0,4,0,2,,0,28,8,26
NCT03073525,Phase 2,31/05/2017,Actual,atezolizumab,"A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)",A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers,0,2,6,0,,,0,,0,40
NCT03074318,Phase 1/Phase 2,28/09/2017,Actual,avelumab,A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma,Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery,4,8,0,0,0,,0,66,8,54
NCT03075527,Phase 2,10/04/2017,Actual,durvalumab,A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,0,0,0,0,0,,0,18,2,18
NCT03075553,Phase 2,17/05/2017,Actual,nivolumab,"Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)",Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,0,0,1,0,,,0,,0,11
NCT03083808,Phase 2,20/03/2017,Actual,pembrolizumab,A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029,Phase II Trial of Continuation Therapy in Advanced NSCLC,0,0,8,0,,,0,,1,26
NCT03085914,Phase 1/Phase 2,02/05/2017,Actual,pembrolizumab,"A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)",A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723),,6,12,2,2,,,144,4,110
NCT03087019,Phase 2,25/04/2017,Actual,pembrolizumab,A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,0,2,2,0,,,0,,2,36
NCT03089606,Phase 2,19/04/2017,Actual,pembrolizumab,Pembrolizumab in Systemic Treatment-Na��ve Distant Metastatic Melanoma and Exploration of Use of Baseline 11C-methyl-L-tryptophan (C11-AMT) PET Imaging as a Predictive Imaging Biomarker of Antitumor Response,Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker,0,0,1,0,0,,0,27,0,26
NCT03090737,Phase 2,02/06/2017,Actual,nivolumab,"An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)",Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer,0,26,3,0,1,,0,41,92,95
NCT03091478,Phase 2,12/04/2017,Actual,pembrolizumab,Pembrolizumab in Patients With Leptomeningeal Disease,Pembrolizumab in Patients With Leptomeningeal Disease,0,2,0,0,0,,0,11,4,9
NCT03093428,Phase 2,09/06/2017,Actual,pembrolizumab,"A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)",Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC,0,2,0,0,,,0,,4,78
NCT03094637,Phase 2,06/11/2017,Actual,pembrolizumab,A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With MDS,Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome,0,0,0,0,,,0,,4,70
NCT03095118,Phase 2,07/09/2017,Actual,daratumumab,Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy,Daratumumab in Treatment of PGNMID and C3 GN,0,1,0,0,,,0,,0,11
NCT03098550,Phase 1/Phase 2,15/06/2017,Actual,daratumumab,Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors,"A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread",,,,,2,,,88,120,
NCT03099161,Phase 1,27/06/2017,Actual,pembrolizumab,A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Malignancies,Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062),0,0,0,0,,,0,,0,20
NCT03101566,Phase 2,08/09/2017,Actual,nivolumab,A Multi-Center Randomized Phase II Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer [CA209-9FC],Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,0,8,16,0,14,,2,134,6,120
NCT03102242,Phase 2,01/11/2017,Actual,atezolizumab,Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.,Atezolizumab Immunotherapy in Patients With Advanced NSCLC,0,4,9,0,0,,0,61,1,49
NCT03115801,Phase 2,30/11/2016,Actual,nivolumab,A Phase II Randomized Controlled Trial of Programmed Death -1/Programmed Death Ligand-1(PD-1/PDL-1) Axis Blockade Versus PD-1/PDL-1 Axis Blockade Plus Radiotherapy in Metastatic Genitourinary (Renal/Urothelial) Malignancies,A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers,,,,,2,,,6,4,
NCT03117049,Phase 3,13/06/2017,Actual,ono-4538,"A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)",Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52),0,1100,0,0,,,0,,0,0
NCT03120676,Phase 2,14/04/2017,Actual,atezolizumab,A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma,Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma,0,0,0,0,,,0,,1,2
NCT03121534,Phase 2,22/06/2017,Actual,nivolumab,"A Phase II Study of Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation","Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation",0,0,1,0,,,0,,1,7
NCT03122509,Phase 2,24/04/2017,Actual,durvalumab,Phase II Study to Assess the Efficacy of Durvalumab (MEDI4736) and Tremelimumab Plus Radiotherapy or Ablation in Patients With Metastatic Colorectal Cancer,"A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer",0,8,2,0,2,,0,48,2,38
NCT03122548,Phase 2,14/08/2017,Actual,pembrolizumab,"A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas","Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers",0,1,0,0,1,,0,3,2,3
NCT03123055,Phase 1/Phase 2,20/04/2017,Actual,pembrolizumab,"A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy",A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,0,0,1,0,,,0,,0,27
NCT03126110,Phase 1/Phase 2,25/04/2017,Actual,nivolumab,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",,,,,16,,,268,6,
NCT03130959,Phase 2,12/06/2017,Actual,nivolumab,Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies,A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies,2,20,18,0,28,,,148,184,264
NCT03132467,Early Phase 1,13/06/2017,Actual,durvalumab,"A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer","Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer",0,1,0,0,0,,0,8,0,7
NCT03135262,Phase 1/Phase 2,15/06/2017,Actual,venetoclax,A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),0,10,2,0,0,,4,58,0,42
NCT03136055,Phase 2,20/06/2017,Actual,pembrolizumab,A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,0,10,4,0,6,,0,64,4,56
NCT03138499,Phase 3,26/06/2017,Actual,nivolumab,"Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812)","A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,",,4,10,2,10,,,40,4,22
NCT03138889,Phase 1/Phase 2,09/06/2017,Actual,atezolizumab,"A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors",Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors,0,2,14,0,10,,0,288,32,302
NCT03141177,Phase 3,22/08/2017,Actual,nivolumab,"A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma,10,102,10,0,180,,0,638,712,1152
NCT03142334,Phase 3,09/06/2017,Actual,pembrolizumab,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)",Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564),24,276,24,0,268,,26,1550,310,1498
NCT03157089,Phase 2,02/11/2017,Actual,pembrolizumab,"LUX-Lung IO: A Phase II, Open Label, Non-randomised Study of Afatinib in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung",Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung,0,10,0,0,,,0,,10,28
NCT03158272,Phase 1,25/05/2017,Actual,nivolumab,"A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination With Nivolumab (BMS-936558) in Advanced Malignancies",A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread,0,38,0,0,0,,0,38,0,0
NCT03158688,Phase 3,13/06/2017,Actual,daratumumab,"A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.",,132,18,,16,,,924,42,732
NCT03162224,Phase 1/Phase 2,26/06/2017,Actual,durvalumab,"A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer",Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer,0,0,2,2,0,,0,70,0,66
NCT03163992,Phase 2,26/12/2017,Actual,pembrolizumab,Pembrolizumab in HCC,Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib,0,60,0,0,0,,0,60,0,0
NCT03164616,Phase 3,01/06/2017,Actual,durvalumab,"A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).,76,700,40,4,320,,,1780,,1132
NCT03164772,Phase 1/Phase 2,20/12/2017,Actual,durvalumab,A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC),Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC,0,4,18,0,6,,0,94,22,84
NCT03168438,Phase 1,18/08/2017,Actual,pembrolizumab,"Open-Label Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma",Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma,,,,,,,,,,12
NCT03168464,Phase 1/Phase 2,09/10/2017,Actual,nivolumab,Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632),Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632),0,1,2,0,0,,0,11,5,11
NCT03173560,Phase 2,17/08/2017,Actual,lenvatinib,"A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment",Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma,0,120,0,0,24,,0,662,12,554
NCT03174275,Phase 2,19/12/2017,Actual,durvalumab,Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck,"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",0,0,4,0,1,,0,37,4,32
NCT03178851,Phase 1,20/06/2017,Actual,atezolizumab,A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti-PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma,Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma,4,4,10,0,64,,0,236,12,290
NCT03179410,Phase 2,01/02/2018,Actual,avelumab,PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer,PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer,0,0,4,0,0,,0,15,0,11
NCT03181308,Phase 1,09/11/2017,Actual,opdivo,A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer,Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC,0,0,4,0,0,,0,22,0,18
NCT03187262,Phase 2,27/11/2017,Actual,daratumumab,A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenstr��m Macroglobulinemia,A Study of Daratumumab in Patients With Relapsed or Refractory Waldenstr��m Macroglobulinemia,0,0,0,0,,,0,,0,13
NCT03189719,Phase 3,25/07/2017,Actual,pembrolizumab,"A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),42,800,14,0,198,,28,1222,136,556
NCT03196232,Phase 2,13/09/2017,Actual,pembrolizumab,Phase 2 Study of Epacadostat (INCB024360) With Pembrolizumab (MK3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired Biopsies,Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer,0,1,0,0,2,,0,1,2,0
NCT03197389,Early Phase 1,18/01/2018,Actual,pembrolizumab,"Effect of Pembrolizumab (Keytruda��) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early Breast Cancer.",Effect of Pembrolizumab (Keytruda��) on Biomarkers in Early Breast Cancer.,0,0,0,0,,,0,,0,108
NCT03201250,Phase 1/Phase 2,21/02/2018,Actual,cabozantinib,A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma,Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma,0,2,4,0,,,0,,0,10
NCT03201965,Phase 3,05/10/2017,Actual,daratumumab,"A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis","A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis",6,128,30,2,46,,2,762,50,638
NCT03203473,Phase 2,26/10/2017,Actual,nivolumab,Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study),Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study),0,0,3,0,,,4,,1,75
NCT03204188,Phase 2,22/09/2017,Actual,pembrolizumab,"A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",0,0,3,0,1,,0,14,1,11
NCT03204812,Phase 2,14/07/2017,Actual,durvalumab,"A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Na��ve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC)",Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer,0,0,2,0,3,,0,23,2,22
NCT03206073,Phase 1/Phase 2,07/12/2017,Actual,durvalumab,A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,0,6,16,2,4,,0,62,2,44
NCT03211117,Phase 2,14/08/2017,Actual,pembrolizumab,Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer,"Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",0,0,0,0,,,0,,0,3
NCT03214250,Phase 1/Phase 2,21/07/2017,Actual,nivolumab,"Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,,20,10,,8,,,262,0,216
NCT03215706,Phase 3,24/08/2017,Actual,nivolumab,"A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC,2,120,18,0,120,,0,624,716,1276
NCT03215810,Phase 1,11/10/2017,Actual,nivolumab,A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer,Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer,0,0,2,0,2,,0,18,2,16
NCT03226249,Phase 2,09/11/2017,Actual,pembrolizumab,Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma,PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,0,2,1,0,2,,2,28,0,25
NCT03233724,Phase 1/Phase 2,11/04/2018,Actual,pembrolizumab,"Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas","Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",2,2,4,0,2,,0,16,0,10
NCT03241173,Phase 1/Phase 2,09/10/2017,Actual,nivolumab,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,0,0,12,0,4,,0,96,8,88
NCT03241927,Phase 2,20/12/2017,Actual,pembrolizumab,A Phase II Study Assessing the Effect of Pembrolizumab Induced Changes to the NK Cell Exhaustion Phenotype on the Efficacy of PD-1 Targeted Treatment in Patients With Unresectable Stage III or Stage IV Melanoma,Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT),0,0,0,0,1,,0,0,0,1
NCT03250273,Phase 2,06/11/2017,Actual,nivolumab,A Phase 2 Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,0,0,4,0,4,,0,76,8,80
NCT03251924,Phase 1/Phase 2,01/09/2017,Actual,nivolumab,"A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors",A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors,0,2,6,0,12,,0,88,74,138
NCT03256136,Phase 2,22/11/2017,Actual,nivolumab,"A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer","Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC",0,6,0,0,,,0,,0,12
NCT03256344,Phase 1,19/03/2018,Actual,atezolizumab,A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases,Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases,0,2,2,2,2,,0,70,2,64
NCT03257267,Phase 3,05/09/2017,Actual,cemiplimab,"An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma",Study of Cemiplimab in Adults With Cervical Cancer,,,,,182,,,1002,32,
NCT03259425,Phase 2,03/01/2018,Actual,nivolumab,"Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)","Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",0,0,0,0,0,,1,7,0,6
NCT03260894,Phase 3,07/12/2017,Actual,pembrolizumab,"A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)",Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302),,,,,66,,,180,12,
NCT03264066,Phase 2,23/11/2017,Actual,atezolizumab,"A Phase II, Open-Label, Multicenter, Multicohort Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors",A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors,0,48,0,0,2,,0,160,12,126
NCT03267940,Phase 1,02/10/2017,Actual,atezolizumab,"A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma","Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma",0,62,2,0,4,,0,162,10,100
NCT03271047,Phase 2,18/10/2017,Actual,nivolumab,An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,0,2,6,0,2,,0,130,32,128
NCT03273153,Phase 3,11/12/2017,Actual,atezolizumab,"A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma",A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,0,24,14,0,44,,0,740,190,772
NCT03274804,Phase 1,01/04/2018,Actual,pembrolizumab,A Phase I Trial of Combined PD-1 Inhibition (Pembrolizumab) and CCR5 Inhibition (Maraviroc) for the Treatment of Refractory Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC),Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC,0,1,0,0,,,0,,0,19
NCT03277352,Phase 1/Phase 2,21/11/2017,Actual,pembrolizumab,A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,,1,,,1,,,10,,8
NCT03284424,Phase 2,26/10/2017,Actual,pembrolizumab,"A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)",Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629),8,0,2,2,30,,2,196,158,238
NCT03287050,Phase 2,24/01/2018,Actual,pembrolizumab,"FAST: Feasibility Trial of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma","Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma",0,0,0,0,0,,0,6,0,6
NCT03294304,Phase 2,29/01/2018,Actual,nivolumab,BLASST-1 (Bladder Cancer Signal Seeking Trial): Phase II Trial of Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Radical Cystectomy,"BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy",0,0,0,0,1,,0,34,20,31
NCT03301636,Phase 2,08/12/2017,Actual,nivolumab,A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Adult Patients With Unresectable Stage III or Stage IV Malignant Melanoma,A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma,0,0,0,0,,,0,,0,42
NCT03302234,Phase 3,14/12/2017,Actual,pembrolizumab,"A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ��� 50%) (KEYNOTE-598)",Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598),14,128,2,0,182,,22,866,176,882
NCT03302247,Phase 2,15/01/2018,Actual,nivolumab,Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,0,0,1,0,0,,0,3,0,2
NCT03307785,Phase 1,12/10/2017,Actual,niraparib,"Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer","Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042",,,5,,,,,,,52
NCT03308942,Phase 2,29/09/2017,Actual,niraparib,"Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With a PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer",Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants,2,4,6,,,,,,6,88
NCT03316586,Phase 2,30/11/2017,Actual,nivolumab,A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer,A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer,0,0,1,0,,,1,,1,15
NCT03322540,Phase 2,15/12/2017,Actual,pembrolizumab,"A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1",Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05),,96,,,22,,,278,8,212
NCT03322566,Phase 2,09/01/2018,Actual,pembrolizumab,A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer,A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06),2,46,4,,10,,,446,12,412
NCT03325166,Phase 2,03/11/2017,Actual,pembrolizumab,"The Use of Perfusion MRI Using Ferumoxytol and Small Molecular Weight Gadolinium (Gd) Agents to Assess Response to Pembrolizumab in Brain Metastases and Systemic Lesions in NSCLC: A Comparison of Imaging Modalities to Address Brain Metastases, Pseudoprogression, and Systemic Lesion Tumor Flare (Neuro-Check Pilot)",Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases,0,0,0,0,0,,0,2,0,2
NCT03325816,Phase 1/Phase 2,20/11/2017,Actual,nivolumab,Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer,Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer,0,0,4,0,0,,0,18,0,14
NCT03329846,Phase 3,30/11/2017,Actual,nivolumab,"A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated","An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma",0,2,0,0,2,,0,22,18,36
NCT03329937,Phase 1,12/04/2018,Actual,niraparib,"An Open-Label, Single-arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients",Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer,,1,1,,,,,,,19
NCT03331562,Phase 2,27/12/2017,Actual,pembrolizumab,A SU2C Catalyst �� Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response,A SU2C Catalyst�� Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer,0,2,4,0,4,,0,44,0,42
NCT03332498,Phase 1/Phase 2,24/01/2018,Actual,pembrolizumab,"A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers","Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers",0,2,10,0,2,,0,74,6,66
NCT03333746,Phase 2,21/03/2018,Actual,nivolumab,Phase II Study of Lenalidomide in Combination With Nivolumab In Patients With Relapsed/Refractory Multiple Myeloma,Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma,0,0,0,0,0,,0,1,0,1
NCT03338790,Phase 2,19/12/2017,Actual,nivolumab,"A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer","An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer",0,8,30,0,,,0,,50,496
NCT03340766,Phase 1,16/03/2018,Actual,pembrolizumab,A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL),,4,,,2,,,64,2,52
NCT03341936,Phase 2,15/03/2018,Actual,nivolumab,"Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck","Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN",0,0,1,0,,,0,,1,26
NCT03347123,Phase 1/Phase 2,21/03/2018,Actual,nivolumab,"A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)",A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208),0,2,0,0,0,,0,16,6,20
NCT03349710,Phase 3,15/12/2017,Actual,nivolumab,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer",0,56,4,0,0,,0,40,124,72
NCT03351231,Phase 1/Phase 2,27/11/2017,Actual,nivolumab,"A Phase 1/2a Study of BMS-986242 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1) in Advanced Malignant Tumors",An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer,0,0,1,0,0,,0,5,0,4
NCT03357952,Phase 2/Phase 3,16/11/2017,Actual,daratumumab,"A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Subjects With Relapsed or Refractory Multiple Myeloma","A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma",0,0,2,0,0,,0,20,0,18
NCT03358472,Phase 3,01/12/2017,Actual,pembrolizumab,"A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",,,,,0,,,172,6,
NCT03359850,Phase 1,20/02/2018,Actual,niraparib,"An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients With Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment",Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients,,,2,,,,,,,32
NCT03361865,Phase 3,04/12/2017,Actual,pembrolizumab,"A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)",Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307),,,,,4,,,154,28,
NCT03363776,Phase 1/Phase 2,06/12/2017,Actual,nivolumab,Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors,An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers,0,0,0,0,0,,0,4,16,20
NCT03364049,Phase 1,06/12/2017,Actual,pembrolizumab,Phase 1b Open-label Study of MK-7162 in Combination With Pembrolizumab (MK-3475) +/- Other Therapies in Participants With Advanced Solid Tumors,Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002),0,18,6,0,4,,0,58,6,40
NCT03366844,Phase 1/Phase 2,22/12/2017,Actual,pembrolizumab,Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients With Operable Breast Cancer,Breast Cancer Study of Preoperative Pembrolizumab + Radiation,0,7,8,0,9,,2,50,2,42
NCT03367715,Phase 2,07/02/2018,Actual,nivolumab,"A Phase II, Open-label, Single Arm Trial of Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma","Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma",1,0,0,0,2,,1,8,1,7
NCT03370276,Phase 1/Phase 2,20/12/2017,Actual,nivolumab,A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma,Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,0,4,12,0,8,,0,178,10,168
NCT03371381,Phase 1/Phase 2,02/01/2018,Actual,nivolumab,"An Open-Label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Subjects With Advanced Adenocarcinoma of the Lung","An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung",0,0,0,0,1,,0,11,0,12
NCT03374488,Phase 3,22/12/2017,Actual,pembrolizumab,"A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)",Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma,,,,,0,,,150,18,
NCT03376659,Phase 1/Phase 2,08/08/2018,Actual,durvalumab,"A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma",Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma,0,0,1,0,0,,0,7,1,7
NCT03382899,Phase 2,19/03/2018,Actual,pembrolizumab,A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%),Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer,0,6,20,0,10,,14,174,26,154
NCT03382912,Phase 2,22/03/2018,Actual,nivolumab,A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1,Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer,0,2,8,0,4,,0,88,20,86
NCT03390296,Phase 1/Phase 2,27/12/2017,Actual,avelumab,"An Open-Label Phase Ib/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 mAb, Smoothened Inhibitor, Anti-CD33 mAb, Bcl-2 Inhibitor and Azacitidine as Single-Agents and/or Combinations for the Treatment of Patients With Acute Myeloid Leukemia (AML)","OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia",0,2,8,0,,,0,,8,82
NCT03394885,Phase 1/Phase 2,19/06/2018,Actual,atezolizumab,Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer,Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer,0,1,2,0,1,,1,17,0,14
NCT03396471,Phase 2,01/02/2018,Actual,pembrolizumab,Single-arm Phase 2 Study to Examine Pembrolizumab and Concurrent Radiation to Induce an Abscopal Effect in Patients With Previously Treated Carcinoma of Unknown Primary (CUP16-268),Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary,0,0,0,0,2,,0,11,1,14
NCT03396952,Phase 2,19/04/2018,Actual,pembrolizumab,Prostaglandin Inhibition and Programmed Cell Death Protein 1 (PD-1)/Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA4) Blockade in Melanoma,Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma,0,0,0,0,2,,0,25,1,26
NCT03406715,Phase 2,15/03/2018,Actual,nivolumab,Combination Immunotherapy With Ipilimumab and Nivolumab Plus a Dendritic Cell Based p53 Vaccine (Ad.p53-DC) in Patients With Relapsed Small Cell Lung Cancer (SCLC),Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC),0,0,0,0,0,,0,14,0,14
NCT03406858,Phase 2,07/06/2018,Actual,pembrolizumab,Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer,Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer,0,0,1,0,,,0,,0,12
NCT03412565,Phase 2,26/04/2018,Actual,daratumumab,A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens,A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens,0,10,20,0,32,,0,322,322,354
NCT03414684,Phase 2,30/01/2018,Actual,nivolumab,A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer,Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer,,2,10,,4,,4,144,8,128
NCT03414983,Phase 2/Phase 3,20/02/2018,Actual,nivolumab,An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer,An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread,,,,,32,,,322,36,
NCT03417154,Phase 2,13/08/2018,Actual,nivolumab,Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS),Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS,0,0,0,0,,,0,,2,22
NCT03428217,Phase 2,24/04/2018,Actual,cabozantinib,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)",CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma,,16,18,4,50,,,698,290,700
NCT03433703,Phase 2,26/04/2018,Actual,lenvatinib,"A Single-Arm, Multicenter, Phase 2 Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)",Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC),0,0,2,0,0,,0,2,0,0
NCT03434379,Phase 3,15/03/2018,Actual,atezolizumab,"A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma",A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma,2,956,20,0,26,,0,1298,128,350
NCT03435640,Phase 1/Phase 2,15/03/2018,Actual,nivolumab,"A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) With or Without Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies",REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies,2,6,2,0,6,,0,120,2,118
NCT03439293,Phase 2,13/03/2018,Actual,daratumumab,"A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)",A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM),0,0,3,0,1,,0,55,10,53
NCT03442569,Phase 2,09/03/2018,Actual,nivolumab,"Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma","PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC",0,3,7,0,1,,0,54,3,44
NCT03444766,Phase 4,06/03/2018,Actual,nivolumab,Safety Study of Nivolumab for Selected Advanced Malignancies in India,Study of Nivolumab for Advanced Cancers in India,0,100,0,0,0,,0,0,100,0
NCT03447314,Phase 1,26/03/2018,Actual,pembrolizumab,"A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors",Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors,,4,,,,2,,,10,92
NCT03462719,Phase 3,17/04/2018,Actual,venetoclax,"A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).",A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL),0,2,0,0,8,,2,400,28,404
NCT03463161,Phase 2,23/03/2018,Actual,pembrolizumab,"A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy",Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy,0,0,0,0,,,0,,0,2
NCT03465722,Phase 3,26/03/2018,Actual,regorafenib,"An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)",(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST,0,256,28,4,,,0,,100,564
NCT03465891,Phase 2,09/03/2018,Actual,atezolizumab,Two-Arm Parallel Phase 2 Clinical Trial of Atezolizumab With or Without Low Dose Local Radiotherapy (2 x 2Gy) in Patients With Relapsed/Refractory Advanced Stage Follicular Lymphoma,"Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma",0,0,0,0,0,,0,4,0,4
NCT03468985,Phase 2,01/03/2018,Actual,nivolumab,"A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC","Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer",0,0,0,0,0,,0,4,2,6
NCT03470922,Phase 2/Phase 3,11/04/2018,Actual,nivolumab,"A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma",A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma,2,0,10,0,94,,0,582,788,1380
NCT03473925,Phase 2,10/04/2018,Actual,pembrolizumab,A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors,Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034),0,50,10,0,4,,0,206,0,150
NCT03475004,Phase 2,17/09/2018,Actual,pembrolizumab,Phase II Study of Pembrolizumab in Combination With Binimetinib and Bevacizumab in Patients With Refractory Colorectal Cancer,"Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer",2,10,2,0,4,,0,102,6,86
NCT03481556,Phase 1/Phase 2,12/04/2018,Actual,daratumumab,An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma,Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM,0,0,4,0,2,,0,102,16,100
NCT03482453,Phase 1,28/03/2018,Actual,tak-788,"Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Rising Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of TAK-788 Followed by Open-Label, Crossover Evaluation of the Effects of a Low-Fat Meal on TAK-788 Pharmacokinetics and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Subjects","A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants",0,0,6,0,20,,0,118,0,132
NCT03496662,Phase 1/Phase 2,31/08/2018,Actual,nivolumab,A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC),BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC),0,2,10,0,0,,0,80,0,68
NCT03497429,Phase 1,05/04/2018,Actual,niraparib,"A Phase 1, Open-label Study of Niraparib as Single Agent in Patients With Advanced Solid Tumors",A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors,0,18,0,0,,,0,,0,0
NCT03498196,Phase 1/Phase 2,14/12/2018,Actual,avelumab,A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease),A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer,0,0,1,0,0,,0,1,0,0
NCT03498612,Phase 2,09/07/2018,Actual,pembrolizumab,Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases,Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases,0,0,0,0,1,,0,8,0,9
NCT03502681,Phase 1,12/06/2018,Actual,avelumab,"Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients",A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients,0,0,0,0,0,,0,12,0,12
NCT03506048,Phase 2,16/01/2019,Actual,lenvatinib,A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer,Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer,1,0,0,0,0,,0,4,0,3
NCT03506360,Phase 2,19/06/2018,Actual,pembrolizumab,"Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple Myeloma","Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",0,0,0,0,0,,0,12,1,13
NCT03515629,Phase 3,02/07/2018,Actual,pembrolizumab,"A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ���50%","REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer",0,0,0,0,0,,0,10,0,10
NCT03517449,Phase 3,11/06/2018,Actual,pembrolizumab,"A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer",Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]),22,354,62,2,266,,40,1190,358,1014
NCT03532451,Phase 1,22/03/2019,Actual,nivolumab,Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer,Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer,0,0,4,0,0,,0,76,12,80
NCT03553836,Phase 3,12/09/2018,Actual,pembrolizumab,"Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)",Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716),2,10,16,0,158,,2,1598,370,1748
NCT03563716,Phase 2,10/08/2018,Actual,atezolizumab,"A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Na��ve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer",A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Na��ve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,,82,,,2,,,246,46,164
NCT03566485,Phase 1/Phase 2,10/07/2018,Actual,atezolizumab,BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer,Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer,0,0,0,0,0,,0,18,12,18
NCT03572478,Phase 1/Phase 2,14/08/2018,Actual,nivolumab,A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer,Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer,0,0,3,0,,,0,,0,9
NCT03584009,Phase 2,06/09/2018,Actual,venetoclax,"A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy","A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy",0,18,10,0,8,,2,186,16,172
NCT03597009,Phase 1/Phase 2,06/03/2019,Actual,nivolumab,A Phase Ib/II Study of IV Nivolumab and Intrapleural Talimogene Laherparepvec for Patients With Malignant Pleural Effusion,A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion,0,0,0,0,0,,0,1,0,1
NCT03602586,Phase 2,28/09/2018,Actual,pembrolizumab,A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary,Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer,0,0,0,0,1,,0,13,0,14
NCT03617913,Phase 2,19/09/2018,Actual,avelumab,Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer,Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer,0,0,0,0,0,,0,2,0,2
NCT03618641,Phase 2,08/08/2018,Actual,nivolumab,Neoadjuvant Phase II Study of TLR9 Agonist CMP-001 in Combination With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease,CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease,0,0,0,0,,,0,,0,34
NCT03628716,Phase 2,18/09/2018,Actual,atezolizumab,"A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,0,2,0,0,2,,0,82,2,84
NCT03630120,Phase 2,06/08/2018,Actual,cabozantinib,Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer,0,0,0,0,2,,0,10,0,12
NCT03631407,Phase 2,24/09/2018,Actual,pembrolizumab,A Phase 2 Trial to Evaluate the Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC),Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046),0,4,2,0,14,,2,68,4,70
NCT03631706,Phase 3,01/10/2018,Actual,pembrolizumab,"An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer",M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC),,,,,48,,,552,8,
NCT03635983,Phase 3,21/09/2018,Actual,nivolumab,"A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma",A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma,,,,,308,,,636,622,
NCT03637491,Phase 1/Phase 2,15/08/2018,Actual,avelumab,"A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF COMBINATIONS OF AVELUMAB, BINIMETINIB AND TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS","A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors",,2,,,2,,,64,8,64
NCT03644550,Phase 2,04/12/2018,Actual,pembrolizumab,Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma,Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma,0,0,0,0,1,,0,10,7,18
NCT03655444,Phase 1/Phase 2,29/05/2019,Actual,nivolumab,A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy,Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy,0,0,8,0,0,,0,12,0,4
NCT03661723,Phase 2,28/09/2018,Actual,pembrolizumab,Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Na��ve and Bevacizumab Resistant Recurrent Glioblastoma,Pembrolizumab and Reirradiation in Bevacizumab Na��ve and Bevacizumab Resistant Recurrent Glioblastoma,0,2,2,0,12,,10,86,38,90
NCT03662074,Phase 2,07/11/2018,Actual,nivolumab,Phase II Pilot Study of Subsequent Line Gemcitabine and Nivolumab for Advanced SCLC,Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer,0,0,2,0,0,,0,14,0,12
NCT03662659,Phase 2,16/10/2018,Actual,nivolumab,"A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma",An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers,,,,,54,,,306,188,
NCT03663166,Phase 1/Phase 2,20/11/2018,Actual,nivolumab,Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC,Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC),0,0,1,0,1,,0,17,2,17
NCT03664024,Phase 2,30/10/2018,Actual,pembrolizumab,"A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782)","Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)",1,1,2,0,2,,0,116,0,114
NCT03668119,Phase 2,31/10/2018,Actual,nivolumab,"A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)",A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H),0,18,4,0,36,,0,130,292,368
NCT03680521,Phase 2,10/10/2018,Actual,nivolumab,A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma,Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma,0,0,0,0,8,,0,30,4,38
NCT03681951,Phase 2,16/11/2018,Actual,pembrolizumab,"A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors",First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors,,,2,,,,,,2,12
NCT03684811,Phase 1/Phase 2,01/11/2018,Actual,nivolumab,A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation,A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation,0,10,2,0,14,,0,134,70,142
NCT03689855,Phase 2,05/06/2019,Actual,atezolizumab,Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1),Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC,0,0,5,0,0,,0,21,0,16
NCT03690388,Phase 3,05/10/2018,Actual,cabozantinib,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy,6,68,6,0,54,,0,296,56,262
NCT03693300,Phase 2,16/04/2019,Actual,durvalumab,"A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)",A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer,,,,,2,,,212,46,208
NCT03693846,Phase 2,15/02/2019,Actual,nivolumab,A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors,Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors,0,0,3,0,,,0,,0,8
NCT03704467,Phase 1,04/03/2019,Actual,avelumab,"A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer,0,0,0,0,0,,0,3,0,3
NCT03713944,Phase 2,15/11/2018,Actual,atezolizumab,A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-na��ve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139,Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-na��ve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,,3,5,,2,,1,28,1,20
NCT03717155,Phase 2,30/10/2018,Actual,avelumab,"A Phase IIa, Single-arm, Multicenter Study to Investigate the Clinical Activity and Safety of Avelumab in Combination With Cetuximab Plus Gemcitabine and Cisplatin in Participants With Advanced Squamous NSCLC",Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC,0,0,0,0,,,0,,0,43
NCT03723915,Phase 2,14/11/2018,Actual,pembrolizumab,A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma,Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer,0,1,1,0,0,,0,12,3,9
NCT03724968,Phase 2,17/01/2019,Actual,nivolumab,A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression,Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression,0,0,0,0,,,0,,0,4
NCT03729245,Phase 3,18/12/2018,Actual,nivolumab,A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma,A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC),,,,,558,,,658,30,
NCT03730012,Phase 1/Phase 2,19/06/2019,Actual,atezolizumab,Phase 1/2 Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML),A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML),0,0,4,0,0,,0,22,0,18
NCT03739138,Phase 1,18/12/2018,Actual,pembrolizumab,"A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Solid Tumors",Intratumoral/Intralesional Administration of MK-4621/JetPEI��� With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002),0,0,0,0,0,,0,36,40,44
NCT03759587,Phase 2,28/12/2018,Actual,niraparib,"A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety of Niraparib in Japanese Patients With Platinum-sensitive, Relapsed Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Achieved CR or PR in the Last Chemotherapy Containing Platinum-based Anticancer Agents",Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer,0,19,0,0,,,0,,0,0
NCT03759600,Phase 2,26/12/2018,Actual,niraparib,"A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of Niraparib in Japanese Patients With Advanced, Relapsed, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received 3 or 4 Previous Chemotherapy Regimens","Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer",0,20,0,0,,,0,,0,0
NCT03761056,Phase 2,29/01/2019,Actual,axicabtagene ciloleucel,A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12),Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma,1,1,1,,2,,,37,5,33
NCT03770455,Phase 2,25/01/2019,Actual,avelumab,PDL-1 Inhibition With Avelumab and Concurrent Second-generation ADT in African Americans With Castrate-resistant Metastatic Prostate Cancer,Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC,0,0,5,0,,,0,,0,0
NCT03775486,Phase 2,21/12/2018,Actual,durvalumab,"A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)",Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION),0,164,4,0,10,,0,528,0,370
NCT03776864,Phase 2,26/09/2019,Actual,pembrolizumab,A Phase II Trial of Umbralisib and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,1,0,0,0,2,,0,4,0,5
NCT03781960,Phase 2,31/07/2019,Actual,nivolumab,Phase II Trial of Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma,Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma,0,2,1,0,0,,0,7,1,3
NCT03782064,Phase 2,22/02/2019,Actual,nivolumab,A Phase II Trial of Vaccination With Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma,Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma,,,,,1,,,1,0,
NCT03785925,Phase 2,29/04/2019,Actual,nivolumab,"A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients",A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer,1,2,2,0,20,,0,155,25,171
NCT03787095,Phase 1/Phase 2,13/08/2019,Actual,cemiplimab,"Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: A Phase I/II, Double-blind, Placebo-controlled, Ascending Multiple Dose Study",Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART,0,0,0,0,4,,2,6,0,8
NCT03789110,Phase 2,08/03/2019,Actual,nivolumab,NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer,NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer,0,1,0,0,,,2,,0,27
NCT03794544,Phase 2,08/03/2019,Actual,durvalumab,"A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)",Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer,0,4,10,0,6,,0,162,4,150
NCT03811834,Phase 1,22/01/2019,Actual,mobocertinib,"A Phase 1 Study to Assess Absolute Bioavailability of TAK-788 and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]-TAK-788 in Male Healthy Subjects","A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants",0,0,1,1,2,,0,5,0,5
NCT03823131,Phase 2,02/05/2019,Actual,pembrolizumab,"The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat","Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat",0,12,2,0,4,,0,24,0,14
NCT03824704,Phase 2,23/08/2019,Actual,nivolumab,"A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)",A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES),0,0,0,0,0,,0,1,0,1
NCT03829332,Phase 3,13/03/2019,Actual,pembrolizumab,"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-na��ve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)",Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na��ve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007),20,414,2,0,124,,12,1070,88,762
NCT03834519,Phase 3,02/05/2019,Actual,pembrolizumab,"A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)",Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010),2,322,10,4,206,,2,1320,70,1236
NCT03834623,Phase 2,14/05/2019,Actual,nivolumab,A Phase II Biomarker Trial of Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma,Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma,0,0,4,0,6,,0,40,0,42
NCT03850444,Phase 3,01/08/2016,Actual,pembrolizumab,"A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Na��ve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)",Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study,0,524,0,0,,,0,,0,0
NCT03873493,Phase 2,14/01/2020,Actual,venetoclax,"A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia",A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia,0,0,0,0,0,,0,14,0,14
NCT03874325,Phase 2,26/04/2019,Actual,durvalumab,A Phase II Trial With Safety Run-in of Neoadjuvant Therapy With an Aromatase Inhibitor in Combination With Durvalumab (MEDI4736) in Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer,Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer,0,0,1,0,1,,0,15,3,14
NCT03875092,Phase 3,21/04/2017,Actual,pembrolizumab,"A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study,0,250,0,0,0,,0,250,0,0
NCT03875235,Phase 3,16/04/2019,Actual,durvalumab,"A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers",Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1),2,772,28,,,,,58,,510
NCT03892642,Phase 1/Phase 2,01/05/2019,Actual,avelumab,Phase Ib Study of Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer (ABC Trial),Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer,0,0,2,0,0,,0,18,0,16
NCT03894540,Phase 1,22/03/2019,Actual,pembrolizumab,"A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid Tumours",Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours,,2,2,2,8,,,42,,32
NCT03903640,Phase 2,14/10/2019,Actual,nivolumab,Phase II Study of Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis,Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis,0,0,0,0,0,,0,2,0,2
NCT03905135,Phase 1,07/06/2019,Actual,avelumab,A Phase 1 Study of Interleukin-15 in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies,Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies,0,4,6,0,0,,0,16,0,6
NCT03910439,Phase 2,17/10/2019,Actual,avelumab,A Phase II Pilot Study of Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma,Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma,0,0,1,0,0,,0,4,0,3
NCT03922477,Phase 1,08/10/2019,Actual,atezolizumab,"A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia",A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia,0,0,1,0,1,,0,12,1,11
NCT03927105,Phase 2,25/04/2019,Actual,nivolumab,Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma,Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma,0,0,0,0,0,,0,2,4,2
NCT03928327,Phase 1,02/05/2019,Actual,tak-788,A Phase 1 Study of Oral TAK-788 to Evaluate the Drug-Drug Interaction With Itraconazole and Rifampin in Healthy Adult Subjects,A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants,2,0,2,0,38,,0,10,0,44
NCT03933449,Phase 3,29/12/2016,Actual,pembrolizumab,"A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study,0,246,0,0,0,,0,246,0,0
NCT03964337,Phase 2,17/03/2020,Actual,cabozantinib,"A Phase II, Open-Label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC)",Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer,0,0,0,0,0,,0,6,0,6
NCT03971474,Phase 2,28/05/2019,Actual,pembrolizumab,A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study),Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial),2,6,22,0,4,,2,264,8,236
NCT03988647,Phase 2,24/07/2019,Actual,pembrolizumab,A Phase 2 Study of Palliative Radiation Therapy and Anti-PD-1/PD-L1 Checkpoint Blockade in Patients With Metastatic Merkel Cell Carcinoma,Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma,0,0,0,0,0,,0,1,0,1
NCT04003610,Phase 2,14/05/2020,Actual,pembrolizumab,"A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205)",Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205),0,3,0,0,0,,0,5,1,3
NCT04034225,Phase 1/Phase 2,11/11/2019,Actual,pembrolizumab,"An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck",Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN,0,8,0,0,0,,4,50,2,36
NCT04052204,Phase 1/Phase 2,30/12/2019,Actual,avelumab,A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukin(NKTR-214) With or Without Talazoparib or Enzalutamide in Participants With Locally Advanced or Metastatic Solid Tumors,Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors,0,0,0,0,0,,0,3,0,3
NCT04068181,Phase 2,22/01/2020,Actual,pembrolizumab,Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy,Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).,0,0,0,0,0,,,142,6,136
NCT04075604,Phase 2,18/10/2019,Actual,nivolumab,"Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer >= 2 cm With Safety Run-in, Assessing Nivolumab + Palbociclib + Anastrozole",A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer,0,0,2,0,8,,0,28,12,42
NCT04088500,Phase 2,03/09/2020,Actual,nivolumab,"A Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab Induction",A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma,0,1,0,0,0,,0,5,0,4
NCT04089553,Phase 2,29/08/2019,Actual,durvalumab,"An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients With Prostate Cancer","An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer",2,0,16,0,12,,0,104,8,94
NCT04098068,Phase 2,25/01/2018,Actual,mk-3475,Phase 2 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors,Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D),0,0,2,0,0,,0,12,0,10
NCT04099277,Phase 1,28/10/2019,Actual,pembrolizumab,A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors,A Study of LY3435151 in Participants With Solid Tumors,0,1,0,0,1,,0,0,1,1
NCT04118166,Phase 2,01/10/2019,Actual,nivolumab,Phase 2 Study of Ipilimumab Plus Nivolumab in Combination With Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma,Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma,4,1,1,0,8,,0,22,0,24
NCT04146038,Phase 2,26/10/2020,Actual,venetoclax,Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease,"Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease",0,0,0,0,,,0,,1,4
NCT04150562,Phase 2,26/05/2020,Actual,avelumab,Phase II Trial of Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma,Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma,0,0,0,0,0,,0,2,0,2
NCT04154943,Phase 2,10/03/2020,Actual,cemiplimab,A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC),Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma,,1,,,,,,75,13,69
NCT04173507,Phase 2,14/02/2020,Actual,avelumab,A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study),Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial),1,1,11,0,1,,0,41,0,29
NCT04301778,Phase 2,24/08/2021,Actual,durvalumab,A Phase II Study of Durvalumab (MEDI4736) in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma.,Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma,0,0,3,0,0,,0,5,0,2
NCT04410445,Phase 3,27/07/2020,Actual,nivolumab,"A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)",Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence,0,4,0,0,64,,6,1298,266,1422
NCT04426825,Phase 2,09/09/2020,Actual,atezolizumab,"A Single Arm, Phase II Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Pretreated With Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitors",A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer,0,23,0,0,,,0,,0,0
NCT04434560,Phase 2,04/11/2020,Actual,nivolumab,"A Phase II Trial of Surgery and Stereotactic Radiosurgery With Neoadjuvant Nivolumab and Ipilimumab in Patients With Surgically-resectable, Solid Tumor Brain Metastases",Neoadjuvant Immunotherapy in Brain Metastases,0,0,0,0,0,,0,2,0,2
NCT04439214,Phase 2,31/05/2016,Actual,nivolumab,MATCH Treatment Subprotocol Z1D: Nivolumab in Patients With Tumors With Mismatch Repair Deficiency,Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D),0,2,4,0,2,,0,40,1,35
NCT04441255,Phase 1,01/07/2020,Actual,tak-788,"A Phase 1, Randomized, 2-Period, 2-Sequence, Crossover Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics in Healthy Adult Subjects",A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants,0,2,6,0,2,,0,26,0,20
NCT04442581,Phase 2,20/04/2021,Actual,pembrolizumab,A Phase 2 Trial of Cabozantinib and Pembrolizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma,Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer,0,0,0,0,0,,0,2,0,2
NCT04510285,Phase 2,10/08/2020,Actual,pembrolizumab,A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection,A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection,0,0,0,0,1,,0,0,0,1
NCT04515394,Phase 2,28/01/2021,Actual,tepotinib,A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE),Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE),0,0,0,0,0,,0,3,0,3
NCT04676412,Phase 3,23/10/2019,Actual,pembrolizumab,"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-na��ve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)",Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na��ve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study,0,214,0,0,0,,0,214,0,0
NCT04685499,Phase 2,03/05/2021,Actual,pembrolizumab,"Phase 2 Study of OBP-301 (Telomelysin ���) in Combination With Pembrolizumab and Stereotactic Body Irradiation in Patients With Head and Neck Squamous Cell Carcinoma With Inoperable, Recurrent or Progressive Disease","Phase 2 Study of OBP-301 (Telomelysin���) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease",0,0,0,0,0,,0,1,0,1
NCT04696055,Phase 2,03/02/2021,Actual,pembrolizumab,An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors,Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors,0,44,4,0,20,,2,134,62,114
NCT04730349,Phase 1/Phase 2,03/06/2021,Actual,nivolumab,"Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)","A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer",,,,,2,,,20,8,
NCT04800627,Phase 1/Phase 2,29/03/2021,Actual,pembrolizumab,A Phase I/II Trial of Pevonedistat in Combination With Pembrolizumab in Patients With dMMR/MSI-H Cancers,Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor,0,0,0,0,,,0,,0,2
NCT04969861,Phase 2/Phase 3,09/03/2022,Actual,pembrolizumab,"A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined With Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma With PD-L1 Expressing Tumors (PROPEL-36)",BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36),0,0,0,0,,,0,,0,2
NCT05249569,Phase 2,04/11/2022,Actual,avelumab,"Multi-center Phase II Open-label Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma","Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma",0,0,0,0,,,0,,0,1
NCT05751629,Phase 2,15/11/2018,Actual,niraparib,"Cohort A: PARP Inhibitor-Na��ve Platinum-Resistant Ovarian Cancer Treatment Cohort With TSR-042, Bevacizumab, and Niraparib","Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer",0,1,2,0,5,,0,36,6,32